

PCL Department Publications (2013)

Al-Awar R

Getlik M, Wilson BJ, Morshed MM, Watson ID, Tang D, Subramanian P, **Al-awar R**. Rearrangement of 4-amino-3-halo-pyridines by nucleophilic aromatic substitution. *J Org Chem.*; 78(11):5705-10, 2013.

Yu W, Smil D, Li F, Tempel W, Fedorov O, Nguyen KT, Bolshan Y, **Al-Awar R**, Knapp S, Arrowsmith CH, Vedadi M, Brown PJ, Schapira M. Bromo-deaza-SAH: a potent and selective DOT1L inhibitor. *Bioorg Med Chem.*; 21(7):1787-94,m 2013.

Senisterra G, Wu H, Allali-Hassani A, Wasney GA, Barsyte-Lovejoy D, Dombrovski L, Dong A, Nguyen KT, Smil D, Bolshan Y, Hajian T, He H, Seitova A, Chau I, Li F, Poda G, Couture JF, Brown PJ, **Al-Awar R**, Schapira M, Arrowsmith CH, Vedadi M. Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5. *Biochem J.*; 449(1):151-9, 2013.

Bolshan Y, Getlik M, Kuznetsova E, Wasney G, Hajian T, Poda G, Nguyen K, Wu H, Dombrovski L, Dong A, Schapira M, Arrowsmith C, Brown P, **Al-awar R**, Vedadi M, Smil D. "Synthesis, Optimization, and Evaluation of Novel Small Molecules as Antagonists of WDR5-MLL Interaction." *ACS Medicinal Chemistry Letters.*, 4(3): 353-357, 2013.

Brands B

Rush B, Castel S, **Brands B**, Toneatto T, Veldhuizen S. Validation and comparison of diagnostic accuracy of four screening tools for mental disorders in people seeking treatment for substance use disorders. *J Subst Abuse Treat.*; 44(4):375-83, 2013.

Longman-Mills, S. , González, W. Y., Meléndez, M. O., García, M. R., Gómez, J. D., Juárez, C. G., Martínez, E.A., Peñalba, S. J., Pizzanelli, E.M., Solórzano, L.I., Wright, M.G. M., Cumsille, F. , De La Haye, W. , Sapag, J., Khenti, A. , Hamilton, H.A., Erickson, P.G., **Brands, B.**, Flam-Zalcman, R. , Simpson, S., Wekerle, C. and Mann, R.E. Exploring child maltreatment and its relationship to alcohol and cannabis use in selected Latin American and Caribbean countries. *Child Abuse Negl*; 37(1):77-85, 2013.

Burnham WM

Jeffrey M, Lang M, Gane J, Wu C, **Burnham WM**, Zhang L. A reliable method for intracranial electrode implantation and chronic electrical stimulation in the mouse brain. *BMC Neurosci.*; 14:82, 2013.

Taha AY, Trepanier MO, Ciobanu FA, Taha NM, Ahmed M, Zeng Q, Cheuk WI, Ip B, Filo E, Scott BW, **Burnham WM**, Bazinet RP. A minimum of 3 months of dietary fish oil

supplementation is required to raise amygdaloid afterdischarge seizure thresholds in rats--implications for treating complex partial seizures. *Epilepsy Behav.*; 27(1):49-58, 2013.

Dorian P

McKelvie RS, Moe GW, Ezekowitz JA, Heckman GA, Costigan J, Ducharme A, Estrella-Holder E, Giannetti N, Grzeslo A, Harkness K, Howlett JG, Kouz S, Leblanc K, Mann E, Nigam A, O'Meara E, Rajda M, Steinhart B, Swiggum E, Le VV, Zieroth S, Arnold JM, Ashton T, D'Astous M, **Dorian P**, Haddad H, Isaac DL, Leblanc MH, Liu P, Rao V, Ross HJ, Sussex B. The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure. *Can J Cardiol*; 29(2):168-81, 2013.

Suman-Horduna I, Roy D, Frasure-Smith N, Talajic M, Lespérance F, Blondeau L, **Dorian P**, Khairy P, on behalf of the AF-CHF trial investigators. Quality of life and functional capacity in patients with atrial fibrillation and congestive heart failure. *J Am Coll Cardiol*; 61(4):455-60, 2013.

Glover BM, Hu X, Aves T, Ramadeen A, Zou L, Leong-Poi H, Fujii H, **Dorian P**. Dronedaron and Captisol-enabled Amiodarone in an experimental cardiac arrest. *J Cardiovasc Pharmacol*; 61(5):385-90, 2013.

Thibault B, Harel F, Ducharme A, White M, Ellenbogen KA, Frasure-Smith N, Roy D, Philippon F, **Dorian P**, Talajic M, Dubuc M, Guerra PG, Macle L, Rivard L, Andrade J, Khairy P; LESSER-EARTH Investigators. Cardiac resynchronization therapy in patients with heart failure and a QRS complex <120 milliseconds: The evaluation of resynchronization therapy for heart failure (LESSER-EARTH) trial. *Circulation* .; 127(8):873-81, 2013.

Hess PL, Laird A, Edwards R, Bardy GH, Bigger JT, Buxton AE, Moss AJ, Lee KL, Hall WJ, Steinman R, **Dorian P**, Al Hallstrom PD, Cappato R, Kadish AH, Kudenchuk PJ, Mark DB, Al-Khatib SM, Piccini JP, Inoue LY, Sanders GD. Survival benefit of primary prevention implantable cardioverter-defibrillator therapy after myocardial infarction: Does time to implant matter? A meta-analysis using patient-level data from 4 clinical trials. *Heart Rhythm* .; 10(6):828-35, 2013.

Connolly SJ, Eikelboom J, **Dorian P**, Hohnloser SH, Gretler DD, Sinha U, Ezekowitz MD. Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa) *Eur Heart J*;34(20):1498-505, 2013.

Yu J, Ramadeen A, Tsui AK, Hu X, Zou L, Wilson DF, Esipova TV, Vinogradov SA, Leong-Poi H, Zamiri N, Mazer CD, **Dorian P**, Hare GM. Quantitative assessment of brain microvascular and tissue oxygenation during cardiac arrest and resuscitation in pigs. *Anaesthesia*; 68:723-35, 2013. [Epub ahead of print]

Atzema CL, Austin PC, Chong AS, **Dorian P**. Factors associated with 90-day death after emergency department discharge for atrial fibrillation. *Ann Emerg Med*; 61(5):539-48, 2013.

Hu X, Ramadeen A, Laurent G, So PP, Baig E, Hare GM, **Dorian P**. The effects of an automatic, low pressure and constant flow ventilation device versus manual ventilation during cardiovascular resuscitation in a porcine model of cardiac arrest. *Resuscitation*; 84(8):1150-5, 2013.

Gao D, VanHerendael H, Alshengeiti L, **Dorian P**, Mangat I, Korley V, Ahmad K, Golovchiner G, Aves T, Pinter A. Mexiletine as an adjunctive therapy to amiodarone reduces the frequency of ventricular tachyarrhythmia events in patients with an implantable defibrillator. *J Cardiovasc Pharmacol*; 62(2):199-204, 2013.

Allan KS, Wong N, Aves T, **Dorian P**. The benefits of a simplified method for CPR training of medical professionals: A randomized controlled study. *Resuscitation*; 84(8):1119-24, 2013.

Connolly SJ, Philippon F, Longtin Y, Casanova A, Birnie DH, Exner DV, **Dorian P**, Prakash R, Alings M, Krahn AD. Randomized cluster crossover trials for reliable, efficient, comparative effectiveness testing: design of the Prevention of Arrhythmia Device Infection Trial (PADIT). *Can J Cardiol*; 29(6):652-8, 2013.

Atzema CL, **Dorian P**, Ivers NM, Chong AS, Austin PC. Evaluating early repeat emergency department use in patients with atrial fibrillation: A population-based analysis. *Am Heart J*; 165(6):939-48, 2013.

Yung D, Birnie D, **Dorian P**, Healey JS, Simpson CS, Crystal E, Krahn AD, Khaykin Y, Cameron D, Chen Z, Lee DS. Survival after implantable cardioverter- defibrillator implantation in the elderly. *Circulation.*; 127(24):2383-92, 2013.

Atzema CL, Austin PC, Miller E, Chong AS, Yun L, **Dorian P**. A population-based description of atrial fibrillation in the emergency department, 2002 to 2010. *Ann Emerg Med.*; 62(6):570-577, 2013.

Anagran P, **Dorian P**. Antiarrhythmic drugs in atrial fibrillation: Do they have a future? *Can J Cardiol.*; 29(10):1158-64, 2013.

Dorian P, Burk CT, Mullin CM, Bubien R, Godejohn D, Reynolds MR, Lakkireddy DR, Wimmer AP, Bhandari A, Spertus J. Interpreting changes in quality of life in atrial fibrillation: How much change is clinically meaningful? *Am Heart J.*; 166(2):381-7, 2013.

Dorian P, Angaran P. β -Blockers and Atrial Fibrillation: Hypertension and Other Medical Conditions Influencing Their Use. *Can J Cardiol.* 2013 Oct 9.

Gandhi S, **Dorian P**, Greenlaw N, Tardif JC, Steg PG, Huynh T, Wong GC, Love MP, Poirier P, Goodman SG; Prospective Observational Longitudinal Registry of Patients With Stable Coronary Artery Disease CLARIFY Registry Investigators. Characteristics and evidence-based management of stable coronary artery disease patients in Canada compared with the rest of the world: insights from the CLARIFY registry. *Can J Cardiol.*; 30(1):132-7, 2013.

Levitt K, Aves T, **Dorian P**, Pinter A. Lack of difference in T wave variability between patients at risk of sudden cardiac death and healthy subjects. *J Electrocardiol.*; 47(2):251-6, 2013.

Moayedi Y, Abdel-Qadir HM, **Dorian P**. Evaluation and care of a patient with new-onset atrial fibrillation. *CMAJ*; 186(3):204-5, 2013.

Canadian Cardiovascular Society Heart Failure Management Primary Panel: Moe GW, Ezekowitz JA, O'Meara E, Howlett JG, Fremes SE, Al-Hesayen A, Heckman GA, Ducharme A, Estrella-Holder E, Grzeslo A, Harkness K, Lepage S, McDonald M, McKelvie RS, Nigam A, Rajda M, Rao V, Swiggum E, Virani S, Van Le V, Zieroth S; Secondary Panel: Arnold JM, Ashton T, D'Astous M, **Dorian P**, Giannetti N, Haddad H, Isaac DL, Kouz S, Leblanc MH, Liu P, Ross HJ, Sussex B, White M. The 2013 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: focus on rehabilitation and exercise and surgical coronary revascularization. *Can J Cardiol*; 30(3):249-63, 2013.

Dorian P, Angaran P. Beta blockers and atrial fibrillation: Hypertension and other medical conditions influencing their use. *Can J Cardiol* 2013 Oct 9 [Epub ahead of print]

Rasooli M, Foomany FH, Balasundaram K, Masse S, Zamiri N, Ramadeen A, Hu X, **Dorian P**, Nanthakumar K, Beheshti S, Umapathy K. Blind source separation in characterizing ECG pre-shock waveforms during ventricular fibrillation. *Conf Proc IEEE Eng Med Biol Soc.*; 5833-6, 2013.

Endrenyi L

Endrenyi L, Tothfalusi L. Determination of bioequivalence for drugs with narrow therapeutic index: reduction of the regulatory burden. *J Pharm Pharm Sci.*; 16(5):676-82, 2013.

Tothfalusi L, **Endrenyi L**. Approvable generic carbamazepine formulations may not be bioequivalent in target patient populations. *Int J Clin Pharmacol Ther.*; 51(6):525-8, 2013.

Özdemir V, Badr KF, Dove ES, **Endrenyi L**, Geraci CJ, Hotez PJ, Milius D, Neves-Pereira M, Pang T, Rotimi CN, Sabra R, Sarkissian CN, Srivastava S, Tims H, Zgheib NK, Kickbusch I. Crowd-funded micro-grants for genomics and "big data": an actionable idea connecting small (artisan) science, infrastructure science, and citizen philanthropy. *OMICS.*; 17(4):161-72, 2013.

Chow SC, Wang J, **Endrenyi L**, Lachenbruch PA. Scientific considerations for assessing biosimilar products. *Stat Med.* 10; 32(3):370-81, 2013.

Zhang N, Yang J, Chow SC, **Endrenyi L**, Chi E. Impact of variability on the choice of biosimilarity limits in assessing follow-on biologics. *Stat Med.* 10; 32(3):424-33, 2013.

Endrenyi L, Chang C, Chow SC, Tothfalusi L. On the interchangeability of biologic drug products. *Stat Med.* 10; 32(3):434-41, 2013.

Chow SC, **Endrenyi L**, Lachenbruch PA. Comments on the FDA draft guidance on biosimilar products. *Stat Med.* 10; 32(3):364-9, 2013.

Endrenyi L. Current issues in biowaivers and biosimilars. *Expert Rev. Clin. Pharmacol.* 6: 139-142, 2013.

Finkelstein Y

Demirjian A, **Finkelstein Y**, Nava-Ocampo A, Arnold A, Jones S, Monuteaux M, Sandora TJ, Patterson A, Harper MB. A randomized controlled trial of a vancomycin loading dose in children. *Pediatr Infect Dis J.*; 32(11):1217-23, 2013.

Etoom Y, Banihani R, **Finkelstein Y**. Critical review of: Efficacy of immunoglobulin plus prednisone for prevention of coronary artery prednisolone for prevention of coronary abnormalities in severe Kawasaki disease (RAISE study): a randomized, open-label, blinded-endpoints trial. *J Popul Ther Clin Pharmacol.*; 20(2):e91-4, 2013.

Finkelstein Y, Hutson JR, Freedman SB, Wax P, Brent J; Toxicology Investigators Consortium (Toxic) Case Registry. Drug-induced seizures in children and adolescents presenting for emergency care: current and emerging trends. *Clin Toxicol (Phila).*; 51(8):761-6, 2013.

E. Rosenbloom, **Finkelstein Y**, T Adams-Webber , E. Kozer. Do Antipyretics Prevent the Recurrence of Febrile Seizures in Children? A Systematic Review of Randomized Controlled Trials and Meta Analysis *Eur J Ped Neurol*; 17(6):585-8, 2013.

Imazio M, Belli R, Brucato A, Ferrazzi P, Patrini D, Martinelli L, Polizzi V, Cemin R, Leggieri A, Caforio AL, **Finkelstein Y**, Hoit B, Maisch B, Mayosi BM, Oh JK, Ristic AD, Seferovic P, Spodick DH, Adler Y. Rationale and design of the COLchicine for Prevention of the Post-pericardiotomy Syndrome and Post-operative Atrial Fibrillation (COPPS-2 trial): A randomized, placebo-controlled, multicenter study on the use of colchicine for the primary prevention of the postpericardiotomy syndrome, postoperative effusions, and postoperative atrial fibrillation. *Am Heart J.*; 166(1):13-19.e1, 2013.

Freedman S, Rumantir M, Uleryk E, **Finkelstein Y**. Ondansetron and the risk of cardiac arrhythmias: a systematic review and post-marketing analysis. *Annals of Emergency Medicine* 2013 Dec 4. doi: 10.1016/j.annemergmed.2013.10.026. [Epub ahead of print]

George SR

Cheung EN, **George SR**, Andrade DM, Chow EW, Silversides CK, Bassett AS. Neonatal hypocalcemia, neonatal seizures, and intellectual disability in 22q11.2 deletion syndrome. *Genet Med.*; 16(1):40-4, 2013.

Perreault ML, Hasbi A, O'Dowd BF, **George SR**. Heteromeric dopamine receptor signaling complexes: emerging neurobiology and disease relevance. *Neuropsychopharmacology.*; 39(1):156-68, 2013.

Kabli N, Nguyen T, Balboni G, O'Dowd BF, **George SR**. Antidepressant-like and anxiolytic-like effects following activation of the μ - δ opioid receptor heteromer in the nucleus accumbens. *Mol Psychiatry*. 2013 Sep 24. doi: 10.1038/mp.2013.115. [Epub ahead of print]

Novak G, Fan T, O'Dowd BF, **George SR**. Postnatal maternal deprivation and pubertal stress have additive effects on dopamine D2 receptor and CaMKII beta expression in the striatum. *Int J Dev Neurosci.*;31(3):189-95, 2013.

Perreault ML, Jones-Tabah J, O'Dowd BF, **George SR**. A physiological role for the dopamine D5 receptor as a regulator of BDNF and Akt signalling in rodent prefrontal cortex. *Int J Neuropsychopharmacol.*; 16(2):477-83, 2013.

O'Dowd BF, Nguyen T, Ji X, **George SR**. D5 dopamine receptor carboxyl tail involved in D5-D2 heteromer formation. *Biochem Biophys Res Commun.*; 431(3):586-9, 2013.

Novak G, Fan T, O'Dowd BF, **George SR**. Striatal development involves a switch in gene expression networks, followed by a myelination event: implications for neuropsychiatric disease. *Synapse.*; 67(4):179-88, 2013.

Perreault ML, Fan T, O'Dowd BF, **George SR**. Enhanced brain-derived neurotrophic factor signaling in the nucleus accumbens of juvenile rats. *Dev Neurosci.*; 35(5):384-95, 2013.

Goldstein BI

Birmaher B, **Goldstein BI**, Axelson DA, Monk K, Hickey MB, Fan J, Iyengar S, Ha W, Diler RS, Goldstein T, Brent D, Ladouceur CD, Sakolsky D, Kupfer DJ. Mood lability among offspring of parents with bipolar disorder and community controls. *Bipolar Disord.*; 15(3):253-63, 2013.

Frey BN, Andreazza AC, Houenou J, Jamain S, **Goldstein BI**, Frye MA, Leboyer M, Berk M, Malhi GS, Lopez-Jaramillo C, Taylor VH, Dodd S, Frangou S, Hall GB, Fernandes BS, Kauer-Sant'Anna M, Yatham LN, Kapczinski F, Young LT. Biomarkers in bipolar disorder: a positional paper from the International Society for Bipolar Disorders Biomarkers Task Force. *Aust N Z J Psychiatry.*; 47(4):321-32, 2013.

Goldstein BI, Liu SM, Schaffer A, Sala R, Blanco C. Obesity and the three-year longitudinal course of bipolar disorder. *Bipolar Disord.*; 15(3):284-93, 2013.

Goldstein BI. In this issue/abstract thinking: NAC attack: is N-acetylcysteine ready for prime time in child and adolescent psychiatry? *J Am Acad Child Adolesc Psychiatry.*; 52(2):111-2, 2013.

Hunt JI, Case BG, Birmaher B, Stout RL, Dickstein DP, Yen S, Goldstein TR, **Goldstein BI**, Axelson DA, Hower H, Strober M, Ryan N, Swenson L, Topor DR, Gill MK, Weinstock LM, Keller MB. Irritability and elation in a large bipolar youth sample: relative symptom severity and clinical outcomes over 4 years. *J Clin Psychiatry.*; 74(1):e110-7, 2013.

Martínez-Ortega JM, **Goldstein BI**, Gutiérrez-Rojas L, Sala R, Wang S, Blanco C. Temporal sequencing of nicotine dependence and bipolar disorder in the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). *J Psychiatr Res.*; 47(7):858-64, 2013.

Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, O'Donovan C, Macqueen G, McIntyre RS, Sharma V, Ravindran A, Young LT, Milev R, Bond DJ, Frey BN, **Goldstein BI**. The evolution of CANMAT Bipolar Disorder Guidelines: past, present, and future. *Bipolar Disord.*; 15(1):58-60, 2013.

Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, O'Donovan C, Macqueen G, McIntyre RS, Sharma V, Ravindran A, Young LT, Milev R, Bond DJ, Frey BN, **Goldstein BI**, Lafer B, Birmaher B, Ha K, Nolen WA, Berk M. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. *Bipolar Disord.*; 15(1):1-44, 2013.

Goldstein BI, Young LT. Toward clinically applicable biomarkers in bipolar disorder: focus on BDNF, inflammatory markers, and endothelial function. *Curr Psychiatry Rep.*; 15(12):425, 2013.

Hower H, Case BG, Hoepfner B, Yen S, Goldstein T, **Goldstein BI**, Birmaher B, Weinstock L, Topor D, Hunt J, Strober M, Ryan N, Axelson D, Kay Gill M, Keller MB. Use of mental health services in transition age youth with bipolar disorder. *J Psychiatr Pract.*; 19(6):464-76, 2013.

Goldstein BI, Strober M, Axelson D, Goldstein TR, Gill MK, Hower H, Dickstein D, Hunt J, Yen S, Kim E, Ha W, Liao F, Fan J, Iyengar S, Ryan ND, Keller MB, Birmaher B. Predictors of first-onset substance use disorders during the prospective course of bipolar spectrum disorders in adolescents. *J Am Acad Child Adolesc Psychiatry.*; 52(10):1026-37, 2013.

Sala R, **Goldstein BI**, Wang S, Flórez-Salamanca L, Iza M, Blanco C. Increased prospective health service use for depression among adults with childhood onset bipolar disorder. *J Pediatr.*; 163(5):1454-7.e1-3, 2013.

Birmaher B, **Goldstein BI**, Axelson DA, Monk K, Hickey MB, Fan J, Iyengar S, Ha W, Diler RS, Goldstein T, Brent D, Ladouceur CD, Sakolsky D, Kupfer DJ. Mood lability among offspring of parents with bipolar disorder and community controls. *Bipolar Disord.*; 15(3):253-63, 2013.

Frey BN, Andreazza AC, Houenou J, Jamain S, **Goldstein BI**, Frye MA, Leboyer M, Berk M, Malhi GS, Lopez-Jaramillo C, Taylor VH, Dodd S, Frangou S, Hall GB, Fernandes BS, Kauer-Sant'Anna M, Yatham LN, Kapczinski F, Young LT. Biomarkers in bipolar disorder: a positional paper from the International Society for Bipolar Disorders Biomarkers Task Force. *Aust N Z J Psychiatry.*; 47(4):321-32, 2013.

Grant DM

Ogawa S, Surapisitchat J, Virtanen C, Ogawa M, Niapour M, Sugamori KS, Wang S, Tamblyn L, Guillemette C, Hoffmann E, Zhao B, Strom S, Laposa RR, **Tyndale RF, Grant DM**, Keller G. Three-dimensional culture and cAMP signaling promote the maturation of human pluripotent stem cell-derived hepatocytes. *Development.*; 140(15):3285-96, 2013.

Witham KL, Butcher NJ, Sugamori KS, Brenneman D, **Grant DM**, Minchin RF. 5-methyl-tetrahydrofolate and the S-adenosylmethionine cycle in C57BL/6J mouse tissues: gender differences and effects of arylamine N-acetyltransferase-1 deletion. *PLoS One.*; 8(10):e77923, 2013.

Hampson D

Gholizadeh S, Tharmalingam S, Macaldaz ME, **Hampson DR**. Transduction of the central nervous system after intracerebroventricular injection of adeno-associated viral vectors in neonatal and juvenile mice. *Hum Gene Ther Methods.*; 24(4):205-13, 2013.

Laura KK, Pacey Ingrid Xuan, Asuka Guan, Dafna Sussman, R. Mark Henkelman, Yan Chen, Christian Thomsen, and. **Hampson DR**. Delayed Myelination in a Mouse Model Fragile X Syndrome. *Human Molecular Genetics*, 22 (19), 3920-3930, 2013.

Harper PA

Wu AM, Dalvi P, Lu X, Yang M, Riddick DS, Matthews J, Clevenger CV, Ross DD, **Harper PA**, Ito S. Induction of multidrug resistance transporter ABCG2 by prolactin in human breast cancer cells. *Mol Pharmacol.*; 83(2):377-88, 2013.

Higgins G

Silenieks LB, Koch E, **Higgins GA**. Silexan, an essential oil from flowers of *Lavandula angustifolia*, is not recognized as benzodiazepine-like in rats trained to discriminate a diazepam cue. *Phytomedicine.*; 20(2):172-7, 2013..

Fletcher PJ, Soko AD, **Higgins GA**. Impulsive action in the 5-choice serial reaction time test in 5-HT_{2c} receptor null mutant mice. *Psychopharmacology (Berl).*; 226(3):561-70, 2013.

Higgins GA, Silenieks LB, Lau W, de Lannoy IA, Lee DK, Izhakova J, Coen K, Le AD, Fletcher PJ. Evaluation of chemically diverse 5-HT_{2c} receptor agonists on behaviours motivated by food and nicotine and on side effect profiles. *Psychopharmacology (Berl).*; 226(3):475-90, 2013.

Hyde LA, Zhang Q, Del Vecchio RA, Leach PT, Cohen-Williams M, Chen L, Wong GT, McHugh NA, Chen J, **Higgins GA**, Asberom T, Li W, Pissarnitski D, Levitan D, Nomeir A, Clader JW, Zhang L, Parker EM. In vivo characterization of a novel γ -secretase inhibitor

SCH697466 in rodents and investigation of strategies for managing Notch-related side effects. *Int. J. Alzheimers Disease*; 823528, 2013.

Lau W, Dykstra C, Silenieks L, Thevarkunnel S, De Lannoy I, Lee D, **Higgins GA**. A back-translation of Pregabalin (Lyrica®) and Carbamazepine (Tegretol®) against evoked and non-evoked endpoints in the rat spared nerve injury model. *Neuropharmacology*; 73: 204-215, 2013.

Higgins GA, Sellers EM, Fletcher PJ. From Obesity to substance abuse: therapeutic opportunities for 5-HT_{2C} receptor agonists. *Trends in Pharmaceutical Sciences*; 34: 560-570, 2013.

Ito S

Yazdani-Brojeni P, Garcia-Bournissen F, Fujii H, Tanoshima R, **Ito S**. Relative bioequivalence of amoxicillin dissolved in breast milk. *Arch Dis Child*. 99(3):258-61, 2013.

Madadi P, Amstutz U, Rieder M, **Ito S**, Fung V, Hwang S, Turgeon J, Michaud V, Koren G, Carleton BC; CPNDS Clinical Recommendations Group. Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy. *J Popul Ther Clin Pharmacol.*; 20(3):e369-96, 2013.

Shaw K, Amstutz U, Castro-Pastrana L, Loo TT, Ross CJ, **Ito S**, Reider MJ, Maher M, Macleod S, Koren G, Hayden MR, Carleton BC. Pharmacogenomic investigation of adverse drug reactions(ADRs): the ADR prioritization tool, APT. *J Popul Ther Clin Pharmacol.*; 20(2):e110-27, 2013.

Science M, **Ito S**, Kitai I. Isoniazid toxicity in a 5-year-old boy. *CMAJ.*; 185(10):894-6, 2013.

Wu AM, Dalvi P, Lu X, Yang M, Riddick DS, Matthews J, Clevenger CV, Ross DD, Harper PA, **Ito S**. Induction of multidrug resistance transporter ABCG2 by prolactin in human breast cancer cells. *Mol Pharmacol.*: 83(2):377-88, 2013.

Ito S. System, crowd, and communal innovation: Can the monks solve the elephant? *Clin Pharmacol ther*; 93:369-371, 2013.

Kish SJ

Boileau I, Payer D, Chugani B, Lobo DS, Houle S, Wilson AA, Warsh J, **Kish SJ**, Zack M. In vivo evidence for greater amphetamine-induced dopamine release in pathological gambling: a positron emission tomography study with [(11)C]-(+)-PHNO. *Mol Psychiatry*. 2013 Dec 10. doi: 10.1038/mp.2013.163. [Epub ahead of print]

Matthews BA, **Kish SJ**, Xu X, Boileau I, Rusjan PM, Wilson AA, Digiacomio D, Houle S, Meyer JH. Greater Monoamine Oxidase A Binding in Alcohol Dependence. *Biol Psychiatry*.

2013 Oct 12. pii: S0006-3223(13)00917-7. doi: 10.1016/j.biopsych.2013.10.010. [Epub ahead of print]

Chiuccariello L, Houle S, Miler L, Cooke RG, Rusjan PM, Rajkowska G, Levitan RD, **Kish SJ**, Kolla NJ, Ou X, Wilson AA, Meyer JH. Elevated monoamine oxidase a binding during major depressive episodes is associated with greater severity and reversed neurovegetative symptoms. *Neuropsychopharmacology.*; 39(4):973-80, 2013.

Payer DE, Behzadi A, **Kish SJ**, Houle S, Wilson AA, Rusjan PM, Tong J, Selby P, George TP, McCluskey T, Boileau I. Heightened D(3) dopamine receptor levels in cocaine dependence and contributions to the addiction behavioral phenotype: a positron emission tomography study with [(11)C]-(+)-PHNO. *Neuropsychopharmacology.*; 39(2):311-8, 2013.

Tong J, Meyer JH, Furukawa Y, Boileau I, Chang LJ, Wilson AA, Houle S, **Kish SJ**. Distribution of monoamine oxidase proteins in human brain: implications for brain imaging studies. *J Cereb Blood Flow Metab.*; 33(6):863-71, 2013.

Rusjan PM, Wilson AA, Mizrahi R, Boileau I, Chavez SE, Lobaugh NJ, **Kish SJ**, Houle S, Tong J. Mapping human brain fatty acid amide hydrolase activity with PET. *J Cereb Blood Flow Metab.*; 33(3):407-14, 2013.

Boileau I, Payer D, Chugani B, Lobo D, Behzadi A, Rusjan PM, Houle S, Wilson AA, Warsh J, **Kish SJ**, Zack M. The D2/3 dopamine receptor in pathological gambling: a positron emission tomography study with [11C]-(+)-propyl-hexahydro-naphtho-oxazin and [11C]raclopride. *Addiction.*;108(5):953-63, 2013.

Koren G (104)

Choi JS, Han JY, Ahn HK, Ryu HM, Kim MY, Chung JH, Nava-Ocampo AA, **Koren G**. Fetal and Neonatal Outcomes in Women Reporting Ingestion of Licorice (*Glycyrrhiza uralensis*) during Pregnancy. *Planta Med* 2013 Jan 8. [Epub ahead of print]

Choi JS, **Koren G**, Nulman I. Pregnancy and isotretinoin therapy. *CMAJ* 2013 Jan. 7. [Epub ahead of print]).

Koren G, Nordeng HM. Selective serotonin reuptake inhibitors and malformations: Case closed? *Semin Fetal Neonatal Med*; 18: 19-22, 2013.

Nordeng H, Lupattelli A, Romøren M, **Koren G**. Neonatal outcomes after gestational exposure to nitrofurantoin. *Obstet Gynecol*; 121 (2 Pt 1): 306-13, 2013.

Neuman G, **Koren G**. Motherisk Update: Reproductive outcomes after assisted conception. *Can Fam Physician*; 59: 33-6, 2013.

Choi JS, **Koren G**, Nulman I. Pregnancy and isotretinoin therapy. *CMAJ* 2013 Jan 7. [Epub ahead of print].

Koren G. Drugs, Pregnancy & Lactation. All pregnant women should receive Tdap vaccine. *Obstet Gynecol News* January 29, 2013.

Stevens SA, Nash K, **Koren G**, Rovet J. Autism characteristics in children with fetal alcohol spectrum disorders. *Child Neuropsychol*; 19: 579-87, 2013.

Riggin L, Ramakrishna J, Sommer DD, **Koren G.** A 2013 updated systematic review & meta-analysis of 36 randomized controlled trials; no apparent effects of non steroidal anti-inflammatory agents on the risk of bleeding after tonsillectomy. *Clin Otolaryngol*; 38: 115-29, 2013.

Ross LE, Grigoriadis S, Mamisashvili L, Vonderporten EH, Roerecke M, Rehm J, Dennis CL, **Koren G**, Steiner M, Mousmanis P, Cheung A. Selected pregnancy and delivery outcomes after exposure to antidepressant medication: a systematic review and meta-analysis. *JAMA Psychiatry*; 70: 436-43, 2013.

Gijsen VM, Hesselink DA, Croes K, **Koren G**, de Wildt SN. Prevalence of renal dysfunction in tacrolimus-treated pediatric transplant recipients: a systematic review. *Pediatr Transplant*; 17: 205-15, 2013.

Choi JS, Han JY, Ahn HK, Ryu HM, Kim MY, Yang JH, Nava-Ocampo AA, **Koren G.** Fetal and neonatal outcomes in women taking domperidone during pregnancy. *J Obstet Gynaecol*; 33: 160-2, 2013.

Matok I, Clark S, Caritis S, Miodovnik M, Umans J, Hankins G, **Koren G.** Comparing the pharmacokinetics of doxylamine/pyridoxine delayed-release combination in nonpregnant women of reproductive age and women in the first trimester of pregnancy. *J Clin Pharmacol*; 53:334-8, 2013.

Visscher H, Ross CJ, Rassekh SR, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Rogers PC, Rieder MJ, Carleton BC, Hayden MR; CPNDS Consortium Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. *Pediatr Blood Cancer*; 60: 1375-81, 2013.

Koren G, Sarkar M, Rosenbaum C, Orrbine E. The maternal drinking history guide: development of a national educational tool. *J Popul Ther Clin Pharmacol*; 20: e42-3, 2013.

Koren G. Treating morning sickness PRN? *Can Fam Physician*; 59: 150-1, 2013 .

Hutson JR, Lubetsky A, Eichhorst J, Hackmon R, **Koren G**, Kapur BM. Adverse placental effect of formic acid on hCG secretion is mitigated by folic acid. *Alcohol Alcohol.*; 48: 283-7, 2013.

Saleem M, Herrmann N, Swardfager W, Oh PI, Shammi P, **Koren G**, Van Uum S, Kiss A, Lanctôt KL. Higher cortisol predicts less improvement in verbal memory performance after cardiac rehabilitation in patients with coronary artery disease. *Cardiovasc Psychiatry Neurol* 2013; 340342, 2013.

Matlow JN, Lubetsky A, Aleksa K, Berger H, **Koren G.** The transfer of ethyl glucuronide across the dually perfused human placenta. *Placenta*; 34: 369-73, 2013.

Koren G, Nordeng H, MacLeod S. Gender differences in drug bioequivalence: time to rethink practices. *Clin Pharmacol Ther*; 93: 260-2, 2013.

Lanctôt KL (31)

Saleem M, Herrmann N, Swardfager WL, Oh PI, Shammi P, Koren G, Van Uum S, Kiss A, **Lanctôt KL.** Cortisol predicts less improvement in verbal memory performance after cardiac rehabilitation in patients with coronary artery disease. *Cardiovasc Psychiatry Neurol*: 340342, 2013.

Swardfager WL, Winer DA, Herrmann N, Winer S, **Lanctôt KL.** IL-17 in post-stroke neurodegeneration. *Neurosci Biobehav Rev.* 2013 Mar; 37(3): 436-47, 2013.

Swardfager WL, Herrmann N, McIntyre SR, Mazereeuw G, Goldberger K, Cha DS, Schwartz Y, **Lanctôt KL.** Potential roles of zinc in the pathophysiology and treatment of major depressive disorder. *Neurosci Biobehav Rev.*; 37(5):911-929, 2013.

Noel-Storr AH, Flicker L, Ritchie CW, Nguyen G, Gupta T, Wood P, Walton J, Desai M, Fraser Solomon D, Molena E, Worrall R, Hayen A, Choudhary P, Ladds E, **Lanctôt KL,** Verhey FR, Mead GE, Clare L, McCleery JM, Fioravanti M, Hyde C, Marcus S, McShane R. Systematic review of the body of evidence for use of biomarkers in the diagnosis of dementia. *Alzheimers Dement*; 9(3):e96-e105, 2013.

Drye LT, Scherer RW, **Lanctôt KL,** Rosenberg PB, Herrmann N, Bachman D, Mintzer JE for the ADMET Research Group. Designing a trial to evaluate potential treatments for apathy in dementia: the Apathy in Dementia Methylphenidate trial (ADMET). *Am J Geriatr Psychiat*; 21(6):549-59, 2013.

Paes B, Mitchell I, Li A, Harimoto T, **Lanctôt KL,** and the CARESS Investigators. Respiratory-related hospitalizations following prophylaxis in the Canadian registry for palivizumab (2005-2012) compared to other international registries. *Clin Dev Immunol*: 1-15. Article ID 917068, 15, 2013.

Herrmann N, **Lanctôt KL,** Hogan D. Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. *Alzheimers Research & Therapy*; 5(Suppl 1):S5-17, 2013.

Mazereeuw G, Herrmann N, Bennett SAL, Swardfager WL, Xu H, Valenzuela N, Fai S, **Lanctôt KL.** Platelet activating factors in depression and coronary artery disease: a potential biomarker related to inflammatory mechanisms and neurodegeneration. *Neurosci Biobehav Rev*; 37(8):1611-21, 2013.

Rosenberg PB, **Lanctôt KL,** Drye LT, Herrmann N, Scherer RW, Bachman DL, Mintzer J for the ADMET investigators. Safety and efficacy of methylphenidate for apathy in

Alzheimer's disease: A randomized, placebo-controlled trial. *J Clin Psychiatry*; 74(8):810-6, 2013.

Geda YE, Schneider LS, Gitlin LN, Miller DS, Smith GS, Bell J, Evans J, Lee M, Porsteinsson A, **Lanctôt KL**, Rosenberg PB, Sultzer DL, Francis PT, Brodaty H, Padala PP, Onyike CU, Ortiz LA, Ancoli-Israel S, Bliwise DL, Martin JL, Vitiello MV, Yaffe K, Zee PC, Herrmann N, Sweet RA, Ballard C, Kin NA, Alfaro C, Murray PS, Schultz S, Lyketsos CG; Neuropsychiatric Syndromes Professional Interest Area of ISTAART. Neuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future. *Alzheimers Dement.*; 9(5):602-8, 2013.

Feinstein A, Lapshin H, O'Connor P, **Lanctôt KL**. Sub-threshold cognitive impairment in multiple sclerosis: the association with cognitive reserve. *J Neurol.*; 260(9):2256-61, 2013.
Swardfager WL, Herrmann N, Mazereeuw G, Goldberger K, Harimoto T, **Lanctôt KL**. Zinc in depression: a meta-analysis. *Biol Psychiatry*; 74(12):872-8, 2013.

Benhabib H, **Lanctôt KL**, Eryavec GM, Li A, Herrmann N. Responsiveness of the QUALID to improved neuropsychiatric symptoms with Alzheimer's disease. *Can Geriatr J*; 16(4): 180-185, 2013.

Saleem M, Ratnam Bandaru VV, Herrmann N, Swardfager WL, Mielke MM, Oh PI, Shammi P, Kiss A, Haughey NJ, Rovinski R, **Lanctôt KL**. Ceramides predicts less improvement in verbal memory performance after cardiac rehabilitation in patients with coronary artery disease. *BMC Geriatr*; 13(1):135, 2013.

Lapshin H, **Lanctôt KL**, O'Connor P, Feinstein A. Assessing the validity of a computerized cognitive screening instrument for patients with multiple sclerosis. *Mult Scler*; 19(14):1905-12, 2013.

Paes B, **Lanctôt KL**. Cost-effectiveness of respiratory syncytial virus prophylaxis in premature infants less than 32 weeks gestational age in Turkey [letter]. *Turk J Pediatr.*; 55(5):564-7, 2013.

Lanctôt KL, O'Regan J, Schwartz Y, Swardfager WL, Saleem M, Oh PI, Herrmann N. Assessing cognitive effects of anticholinergic medications in patients with coronary artery disease. *Psychosomatics*; 55(1):61-68, 2013.

Lanctôt KL, Chau SA, Herrmann N, Drye LT, Rosenberg PB, Scherer RW, Vaidya V, Black SE, Bachman DL, Mintzer J for the ADMET investigators. Effect of methylphenidate on attention and association with apathy in AD patients in a randomized, placebo-controlled trial. *Int Psychogeriatr*; 26(2):239-46, 2013.

Paes B, Mitchell I, Yi H, Li A, **Lanctôt KL**, The CARESS Investigators. Hospitalization for respiratory syncytial virus illness in Down syndrome following prophylaxis with palivizumab. *Pediatric Infectious Disease Journal*; 33(2):e29-33, 2013.

Swardfager W, Winer DA, Herrmann N, Winer S, **Lanctôt KL**. Interleukin-17 in post-stroke neurodegeneration. *Neurosci Biobehav Rev.*; 37(3):436-47, 2013.

Laposa RR

Wisnovsky SP, Wilson JJ, Radford RJ, Pereira MP, Chan MR, **Laposa RR**, Lippard SJ, Kelley SO. Targeting mitochondrial DNA with a platinum-based anticancer agent. *Chem Biol.*; 20(11):1323-8, 2013.

Ogawa S, Surapisitchat J, Virtanen C, Ogawa M, Niapour M, Sugamori KS, Wang S, Tamblyn L, Guillemette C, Hoffmann E, Zhao B, Strom S, **Laposa RR**, **Tyndale RF**, Grant DM, Keller G. Three-dimensional culture and cAMP signaling promote the maturation of human pluripotent stem cell-derived hepatocytes. *Development.*; 140(15):3285-96, 2013.

Sacco R, Tamblyn L, Rajakulendran N, Bralha FN, Tropepe V, **Laposa RR**. Cockayne syndrome b maintains neural precursor function. *DNA Repair (Amst.)*; 12(2):110-20, 2013.

Wong JC, Visanji NP, Dabek MK, **Laposa RR**, Hazrati LN. Dendritic spine density is altered in a mouse model of Cockayne syndrome. *Neuropathol Appl Neurobiol.*; 39(4):437-40, 2013.

Le AD

Zou S, Funk D, Shram MJ, **Lê AD**. Effects of stressors on the reinforcing efficacy of nicotine in adolescent and adult rats. *Psychopharmacology (Berl)*. 2013 Oct 25. [Epub ahead of print]

Higgins GA, Sileniaks LB, Lau W, de Lannoy IA, Lee DK, Izhakova J, Coen K, **Le AD**, Fletcher PJ. Evaluation of chemically diverse 5-HT_{2c} receptor agonists on behaviours motivated by food and nicotine and on side effect profiles. *Psychopharmacology (Berl.)*; 226(3):475-90, 2013.

Lê AD, Funk D, Coen K, Li Z, Shaham Y. Role of corticotropin-releasing factor in the median raphe nucleus in yohimbine-induced reinstatement of alcohol seeking in rats. *Addict Biol.*; 18(3):448-51, 2013.

Le Foll B

Le Foll B, Guranda M, Wilson AA, Houle S, Rusjan PM, Wing VC, Zawertailo L, Busto U, Selby P, Brody AL, George TP, Boileau I. Elevation of dopamine induced by cigarette smoking: novel insights from a [(11)C]-(+)-PHNO PET study in humans. *Neuropsychopharmacology.*; 39(2):415-24, 2013.

Nakajima S, Gerretsen P, Takeuchi H, Caravaggio F, Chow T, **Le Foll B**, Mulsant B, Pollock B, Graff-Guerrero A. The potential role of dopamine D₃ receptor neurotransmission in cognition. *Eur Neuropsychopharmacol*; 23(8):799-813, 2013.

Bani-Fatemi A, Gonçalves VF, Zai C, de Souza R, **Le Foll B**, Kennedy JL, Wong AH, De Luca V. Analysis of CpG SNPs in 34 genes: association test with suicide attempt in schizophrenia. *Schizophr Res.*; 147(2-3):262-8, 2013.

Le Foll B, Di Ciano P, Panlilio LV, Goldberg SR, Ciccocioppo R. Peroxisome proliferator-activated receptor (PPAR) agonists as promising new medications for drug addiction: preclinical evidence. *Curr Drug Targets.*; 14(7):768-76, 2013.

Chiuccariello L, Boileau I, Guranda M, Rusjan PM, Wilson AA, Zawertailo L, Houle S, Busto U, **Le Foll B**. Presentation of smoking-associated cues does not elicit dopamine release after one-hour smoking abstinence: A [11C]-(+)-PHNO PET study. *PLoS One.*; 8(3):e60382, 2013.

Gamaledin I, Guranda M, Scherma M, Fratta W, Makriyannis A, Vadivel SK, Goldberg SR, **Le Foll B**. AM404 attenuates reinstatement of nicotine seeking induced by nicotine-associated cues and nicotine priming but does not affect nicotine- and food-taking. *J Psychopharmacol.*; 27(6):564-71, 2013.

Lev-Ran S, Imtiaz S, Rehm J, **Le Foll B**. Exploring the association between lifetime prevalence of mental illness and transition from substance use to substance use disorders: results from the National Epidemiologic Survey of Alcohol and Related Conditions (NESARC). *Am J Addict.*; 22(2):93-8, 2013.

Le Foll B, Trigo JM, Sharkey KA, Le Strat Y. Cannabis and Δ^9 -tetrahydrocannabinol (THC) for weight loss? *Med Hypotheses.*;80(5):564-7, 2013.

Lev-Ran S, Le Strat Y, Imtiaz S, Rehm J, **Le Foll B**. Gender differences in prevalence of substance use disorders among individuals with lifetime exposure to substances: results from a large representative sample. *Am J Addict.*; 22(1):7-13, 2013.

Lev-Ran S, **Le Foll B**, McKenzie K, George TP, Rehm J. Cannabis use and cannabis use disorders among individuals with mental illness. *Compr Psychiatry.*; 54(6):589-98, 2013.

Lev-Ran S, **Le Foll B**, McKenzie K, George TP, Rehm J. Bipolar disorder and co-occurring cannabis use disorders: characteristics, co-morbidities and clinical correlates. *Psychiatry Res.* 2013; 209(3):459-65, 2013.

Pushparaj A, Hamani C, Yu W, Shin DS, Kang B, Nobrega JN, **Le Foll B**. Electrical stimulation of the insular region attenuates nicotine-taking and nicotine-seeking behaviors. *Neuropsychopharmacology.*; 38(4):690-8, 2013.

Le Foll B, Boileau I. Repurposing buspirone for drug addiction treatment. *Int J Neuropsychopharmacol.*; 16(2):251-3, 2013.

Li PP

Roedding AS, Tong SY, Au-Yeung W, **Li PP**, Warsh JJ. Chronic oxidative stress modulates TRPC3 and TRPM2 channel expression and function in rat primary cortical neurons: relevance to the pathophysiology of bipolar disorder. *Brain Res.*; 1517:16-27, 2013.

Matthews J

Lo, R., and **Matthews, J.** The aryl hydrocarbon receptor and estrogen receptor alpha differentially modulate nuclear factor erythroid-2-related factor 2 (NRF2) transactivation in MCF-7 breast cancer cells. *Toxicol Appl Pharmacol*; 270(2):139-48, 2013.

MacPherson, L., Tamblyn, L., Rajendra, S., Bralha, F., McPherson, J.P., and **Matthews, J.** 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) poly(ADP-ribose) polymerase (TiPARP) is a mono-ADP-ribosyltransferase and repressor of aryl hydrocarbon receptor transactivation. *Nucleic Acid Res.*; 41(3):1604-21, 2013.

Wu, A., Dalvi, p., Lu, X., Yang, M., Riddick, D., **Matthews, J.**, Clevenger, C.V., Ross, D.D., Harper, P., and Ito, S. Identification of a prolactin-responsive STAT5 binding element in the 5'-flanking region of the human BRCP/ABCG2 gene. *Mol. Pharm*;83(2):377-88, 2013.

Matthews, J., and Ahmed, S. AHR and ER mediated toxicology and chemoprevention, In *Advances in Molecular Toxicology volume 7*. Editor: James C Fishbein. Elsevier Amsterdam, The Netherlands 2013.

Matthews, J. Alternative Negative Feedback Control in the Aryl Hydrocarbon Receptor Signaling Pathway. *J of Drug Metabolism and Toxicol*. Invited Editorial, 2013.

McPherson JP

Ondovcik SL, Tamblyn L, **McPherson JP**, Wells PG. Sensitivity to methylmercury toxicity is enhanced in oxoguanine glycosylase 1 knockout murine embryonic fibroblasts and is dependent on cellular proliferation capacity. *Toxicol Appl Pharmacol.*; 270(1):23-30, 2013.

MacPherson L, Tamblyn L, Rajendra S, Bralha F, **McPherson JP**, Matthews J. 2,3,7,8-Tetrachlorodibenzo-p-dioxin poly(ADP-ribose) polymerase (TiPARP, ARTD14) is a mono-ADP-ribosyltransferase and repressor of aryl hydrocarbon receptor transactivation. *Nucleic Acids Res.*; 41(3):1604-21, 2013.

McIntyre RS

Carvalho AF, Hyphantis T, Sales PM, Soeiro-de-Souza MG, MacÃ^ãdo DS, Cha DS, **McIntyre RS**, Pavlidis N. Major depressive disorder in breast cancer: a critical systematic review of pharmacological and psychotherapeutic clinical trials. *Cancer Treat Rev.*; 40(3):349-55, 2013.

Park S, Joo YH, **McIntyre RS**, Kim B. Metabolic Syndrome and Elevated C-Reactive Protein Levels in Elderly Patients With Newly Diagnosed Depression. *Psychosomatics*. pii: S0033-3182(13)00242-9, 2013.

Baskaran A, Cha DS, Powell AM, Jalil D, **McIntyre RS**. Sex differences in rates of obesity in bipolar disorder: postulated mechanisms. *Bipolar Disord.* ;16(1):83-92, 2013.

Kudlow PA, Naylor KT, Xie B, **McIntyre RS**. Cognitive enhancement in Canadian medical students. *J Psychoactive Drugs*.;45(4):360-5, 2013.

McIntyre RS, Cha DS, Jerrell JM, Swardfager W, Kim RD, Costa LG, Baskaran A, Soczynska JK, Woldeyohannes HO, Mansur RB, Brietzke E, Powell AM, Gallagher A, Kudlow P, Kaidanovich-Beilin O, Alsuwaidan M. Advancing biomarker research: utilizing 'Big Data' approaches for the characterization and prevention of bipolar disorder. *Bipolar Disord*.. doi: 10.1111/bdi.12162, 2013. [Epub ahead of print]

MacIsaac SE, Carvalho AF, Cha DS, Mansur RB, **McIntyre RS**. The mechanism, efficacy, and tolerability profile of agomelatine. *Expert Opin Pharmacother*.; 15(2):259-74, 2013.

McIntyre RS, Cha DS, Kim RD, Mansur RB. A review of FDA-approved treatment options in bipolar depression. *CNS Spectr*.; 18 Suppl 1:4-20, 2013.

McIntyre RS. Using measurement strategies to identify and monitor residual symptoms. *J Clin Psychiatry*.; 74 Suppl 2:14-8, 2013.

Liu CS, Carvalho AF, Mansur RB, **McIntyre RS**. Obesity and bipolar disorder: synergistic neurotoxic effects? *Adv Ther*.; 30(11):987-1006, 2013.

Hahn MK, Wolever TM, Arenovich T, Teo C, Giacca A, Powell V, Clarke L, Fletcher P, Cohn T, **McIntyre RS**, Gomes S, Chintoh A, Remington GJ. Acute effects of single-dose olanzapine on metabolic, endocrine, and inflammatory markers in healthy controls. *J Clin Psychopharmacol*.; 33(6):740-6, 2013.

Clayton AH, Locklear JC, SvedsÅrter H, **McIntyre RS**. Sexual functioning in patients with major depressive disorder in randomized placebo-controlled studies of extended release quetiapine fumarate. *CNS Spectr*.; 19(2):182-96, 2013.

Cha DS, Kudlow PA, Baskaran A, Mansur RB, **McIntyre RS**. Implications of epigenetic modulation for novel treatment approaches in patients with schizophrenia. *Neuropharmacology*.; 77:481-6, 2013.

Taylor VH, Forhan M, Vigod SN, **McIntyre RS**, Morrison KM. The impact of obesity on quality of life. *Best Pract Res Clin Endocrinol Metab*.; 27(2):139-46, 2013.

Kuswanto CN, Sum MY, Yang GL, Nowinski WL, **McIntyre RS**, Sim K. Increased body mass index makes an impact on brain white-matter integrity in adults with remitted first-episode mania. *Psychol Med*.; 44(3):533-41, 2013.

McIntyre RS, Tohen M, Berk M, Zhao J, Weiller E. DSM-5 mixed specifier for manic episodes: evaluating the effect of depressive features on severity and treatment outcome using asenapine clinical trial data. *J Affect Disord*.; 150(2):378-83, 2013.

Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, O'Donovan C, Macqueen G, **McIntyre RS**, Sharma V, Ravindran A, Young LT, Milev R, Bond DJ, Frey BN, Goldstein BI, Lafer B, Birmaher B, Ha K, Nolen WA, Berk M. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative

update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. *Bipolar Disord.*; 15(1):1-44, 2013.

McIntyre RS, Powell AM, Kaidanovich-Beilin O, Soczynska JK, Alsuwaidan M, Woldeyohannes HO, Kim AS, Gallaughier LA. The neuroprotective effects of GLP-1: possible treatments for cognitive deficits in individuals with mood disorders. *Behav Brain Res.*; 237:164-71, 2013.

Meyer JH

Tong J, Meyer JH, Furukawa Y, Boileau I, Chang LJ, Wilson AA, Houle S, **Kish SJ**. Distribution of monoamine oxidase proteins in human brain: implications for brain imaging studies. *J Cereb Blood Flow Metab.*; 33(6):863-71, 2013.

Meyer JH. Neurochemical imaging and depressive behaviours. *Curr Top Behav Neurosci.* 14:101-34. 2013.

Matthews BA, Kish SJ, Xu X, Boileau I, Rusjan PM, Wilson AA, Digiacomo D, Houle S, **Meyer JH**. Greater Monoamine Oxidase A Binding in Alcohol Dependence. *Biol Psychiatry.* S0006-3223(13)00917-7, 2013. [Epub ahead of print] PMID: 24269057

Chiuccariello L, Houle S, Miler L, Cooke RG, Rusjan PM, Rajkowska G, Levitan RD, Kish SJ, Kolla NJ, Ou X, Wilson AA, **Meyer JH**. Elevated Monoamine Oxidase A Binding During Major Depressive Episodes Is Associated with Greater Severity and Reversed Neurovegetative Symptoms. *Neuropsychopharmacology.*; 10.1038/npp.2013.297, 2013. [Epub ahead of print] PMID: 24154665

Suridjan I, Rusjan PM, Voineskos AN, Selvanathan T, Setiawan E, Strafella AP, Wilson AA, **Meyer JH**, Houle S, Mizrahi R. Neuroinflammation in healthy aging: A PET study using a novel Translocator Protein 18kDa (TSPO) radioligand, [(18)F]-FEPPA. *Neuroimage.*;84:868-75. doi: 10.1016/j.neuroimage.2013.09.021. Epub 2013.

Risinger R, Bhagwagar Z, Luo F, Cahir M, Miler L, Mendonza AE, **Meyer JH**, Zheng M, Hayes W. Evaluation of safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-820836 in healthy subjects: a placebo-controlled, ascending single-dose study. *Psychopharmacology (Berl).* 2013 Dec 15. [Epub ahead of print].

Tong J, **Meyer JH**, Furukawa Y, Boileau I, Chang LJ, Wilson AA, Houle S, Kish SJ. Distribution of monoamine oxidase proteins in human brain: implications for brain imaging studies. *J Cereb Blood Flow Metab.*; 33(6):863-71, 2013.

Milgram NW

Lazarowski L, Foster ML, Gruen ME, Sherman BL, Case BC, Fish RE, **Milgram NW**, Dorman DC. Acquisition of a visual discrimination and reversal learning task by Labrador retrievers. *Anim Cogn.* 2013 Nov 26. [Epub ahead of print]

Zanghi BM, Cupp CJ, Pan Y, Tissot-Favre DG, **Milgram NW**, Nagy TR, Dobson H. Noninvasive measurements of body composition and body water via quantitative magnetic resonance, deuterium water, and dual-energy x-ray absorptiometry in awake and sedated dogs. *Am J Vet Res.*; 74(5):733-43, 2013.

Zanghi BM, Cupp CJ, Pan Y, Tissot-Favre DG, **Milgram NW**, Nagy TR, Dobson H. Noninvasive measurements of body composition and body water via quantitative magnetic resonance, deuterium water, and dual-energy x-ray absorptiometry in cats. *Am J Vet Res.*; 74(5):721-32, 2013.

Snigdha S, **Milgram NW**, Willis SL, Albert M, Weintraub S, Fortin NJ, Cotman CW. A preclinical cognitive test battery to parallel the National Institute of Health Toolbox in humans: bridging the translational gap. *Neurobiol Aging.*; 34(7):1891-901, 2013.

Pan Y, Araujo JA, Burrows J, de Rivera C, Gore A, Bhatnagar S, **Milgram NW**. Cognitive enhancement in middle-aged and old cats with dietary supplementation with a nutrient blend containing fish oil, B vitamins, antioxidants and arginine. *Br J Nutr.*; 110(1):40-9, 2013.

Mitchell J

Mitchell J. Regulation of hepatic glucose production by Gq-coupled receptors: potential new targets for treatment of type 2 diabetes. *Endocrinology.*; 154(10):3495-7, 2013.

Barbuto R, **Mitchell J.** Regulation of the osterix (Osx, Sp7) promoter by osterix and its inhibition by parathyroid hormone. *J Mol Endocrinol.*; 51(1):99-108, 2013.

Mittmann N

Isogai PK, Rueda S, Rachlis AR, Rourke SB, **Mittmann N**; OHTN Cohort Study Team. Prediction of health preference values from CD4 counts in individuals with HIV. *Med Decis Making.*; 33(4):558-66, 2013.

Chan BC, Nanwa N, **Mittmann N**, Bryant D, Coyte PC, Houghton PE. The average cost of pressure ulcer management in a community dwelling spinal cord injury population. *Int Wound J.*; 10(4):431-40, 2013.

Lathia N, Isogai PK, Walker SE, De Angelis C, Cheung MC, Hoch JS, **Mittmann N.** Eliciting patients' preferences for outpatient treatment of febrile neutropenia: a discrete choice experiment. *Support Care Cancer.*; 21(1):245-51, 2013.

Rourke SB, Gardner S, Burchell AN, Raboud J, Rueda S, Bayoumi AM, Loutfy M, Cooper C, Smieja M, Taylor D, DiPede T, Wobeser W, Major C, Waring V, Fisher M, Cairney J, **Mittmann N**, Salit IE, Crouzat F, Gough K, Ralph E, Sandre R, Kilby D, Rachlis A. Cohort profile: the Ontario HIV Treatment Network Cohort Study (OCS). *Int J Epidemiol.*; 42(2):402-11, 2013.

Cheng I, Lee J, Kiss A, Tyberg J, Kerr F, Schull M, Ramango S, **Mittmann N**, Zwarenstein M. Implementing Wait-Time Reductions under Ontario Government Benchmarks (Pay-for Results): a cluster randomized trial of the effect of a physician-nurse supplementary triage assistance team (MDRN-STAT) on emergency department patient wait times. *BMC Emergency Medicine*; 13:17. 2013 Open access.

Chan BC, Seung SJ, McLean D, Bell H, Bell M, Shear NH, **Mittmann N**. Etanercept patient assistance program: another data source for epidemiological studies? *Advances in Pharmacoepidemiology and Drug Safety*; 2:132, 2013.

Woo KY, Keast D, Parsons N, Sibbald RG, **Mittmann N**. The cost of wound debridement: a Canadian perspective. *International Wound Journal* 2013; Jul 9 doi: 10.1111/iwj.12122 epub ahead of print.

Reaume MN, Leighl NB, **Mittmann N**, Coyle D, Hirsh V, Seymour L, Tu D, Shepherd FA, Graham B, Gridelli C, Perrone F, Di Maio, M Bradbury PA, Evans WK on behalf of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Committee On Economic Analysis. Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial). *Lung Cancer*; 82(1):115-20, 2013.

Whitehurst DT, **Mittmann N**. The value of health economics research in spinal cord injury. *Spinal Cord* ; 51(8): 586-587, 2013.

Chan B, Nanwa N, **Mittmann N**, Bryant D, Coyte P, Houghton P. The average cost of pressure ulcer management in a community dwelling spinal cord injury population. *International Wound Journal*; 10(4): 431-440, 2013.

Lathia N, Isogai PK, De Angelis C, Smith TJ, Cheung M, **Mittmann N**, Hoch JS, Walker S. Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients. *Journal of National Cancer Institute*;105(15):1078-1085, 2013.

Nielson R, Kankaanranta H, Bjermer L, Lange P, Arnetorp S, Hedegaard M, Stenling A, **Mittmann N**. Cost-effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. *Respiratory Medicine*; 107(11):1709-21, 2013.

Tam VC, Ko YJ, **Mittmann N**, Cheung MC, Kumar K, Hassan S, Chan KK. Cost-effectiveness of systemic therapies for metastatic pancreatic cancer. *Current Oncology*; 20(2): e90-e106, 2013.

Koo K, Lam K, **Mittmann N**, Konski A, Dennis K, Zeng L, Lam H, Chow E. Comparing cost-effectiveness analysis of denosumab versus zoledronic acid for the treatment of bone metastases. *Supportive Care in Cancer*; 21(6): 1785-1791, 2013.

Rourke SB, Gardner S, Burchell AN, Major C, Rueda S, Waring V, Fisher M, Raboud J, DiPede T, Taylor D, Cooper C, Cairney J, Rachlis A, **Mittmann N**, Wobeser W, Salit IE, Loutfy M, Crouzat F, Bayoumi A, Gough K, Kilby D, Smieja M, Ralph E, Cohen J, Sandre R. Cohort

Profile: The Ontario HIV Treatment Network Cohort Study (OCS). *International Journal of Epidemiology*; 42(2): 402-411, 2013.

Lathia N, **Mittmann N**, DeAngelis C, Isogai PK, Hoch JS, Cheung MC, Walker SE. Eliciting Patient Preferences for Outpatient Treatment of Febrile Neutropenia: A Discrete Choice Experiment. *Supportive Care in Cancer*.; 21(1): 245-251, 2013.

Evans WK, Wolfson MC, Shin J, Goffin J, Miller AB, Asakawa K, Earle C, **Mittmann N**, Fairclough L, Hoch J, Canadian Cancer Risk Management Model: Evaluation of Cancer Control. *International Journal of Technology Assessment in Health Care*; 29(2): 131-139, 2013.

Mittmann N, Henry B, Murshed S, Tsang, Iazzetta J, Crystal E, Bucci C. Does warfarin use impact hospital length of stay? A retrospective study looking at patients treated for atrial fibrillation. *Hospital Topics*; 9(1): 20-24, 2013.

Isogai PK, Rueda S, Rachlis AR, Rourke SB, **Mittmann N**. Prediction of health preference values from CD4 counts in individuals with HIV. *Medical Decision Making*; 33(4): 558-66, 2013.

Nava-Ocampo AA

Demirjian A, Finkelstein Y, **Nava-Ocampo AA**, Arnold A, Jones S, Monuteaux M, Sandora TJ, Patterson A, Harper MB. A randomized controlled trial of a vancomycin loading dose in children. *Pediatr Infect Dis J.*; 32(11):1217-23, 2013

Choi JS, Han JY, Ahn HK, Ryu HM, Kim MY, Yang JH, **Nava-Ocampo AA**, Koren G. Fetal and neonatal outcomes in women taking domperidone during pregnancy. *J Obstet Gynaecol.*; 33(2):160-2, 2013.

Choi JS, Han JY, Ahn HK, Ryu HM, Kim MY, Chung JH, **Nava-Ocampo AA**, Koren G. Fetal and neonatal outcomes in women reporting ingestion of licorice (*Glycyrrhiza uralensis*) during pregnancy. *Planta Med.*; 79(2):97-101, 2013.

Choi JS, Han JY, Ahn HK, Ryu HM, Kim MY, Chung JH, An GH, **Nava-Ocampo AA**. Foetal and neonatal outcomes in first-trimester pregnant women exposed to abdominal or lumbar radiodiagnostic procedures without administration of radionucleotides. *Intern Med J.*; 43(5):513-8, 2013.

Neuman MG

Neuman MG, French SW, Casey CA, Kharbanda KK, Nanau RM, Rasineni K, McVicker BL, Kong V, Donohue TM Jr. Changes in the pathogenesis of alcohol-induced liver disease -- preclinical studies. *Exp Mol Pathol.*; 95(3):376-84, 2013.

Neuman MG, Nanau RM, Shekh-Ahmad T, Yagen B, Bialer M. Valproic acid derivatives signal for apoptosis and repair in vitro. *Clin Biochem.*; 46(15):1532-7, 2013.

Nanau RM, **Neuman MG**. Adverse drug reactions induced by valproic acid. *Clin Biochem.*; 46(15):1323-38, 2013.

Binazon O, Dubois-Gauche A, Nanau RM, **Neuman MG**. Efficacy and safety of platelet inhibitors. *J Pharm Pharm Sci.*; 16(1):1-39. Review. PubMed PMID: 23683603, 2013.

Neuman MG, McKinney KK, Nanau RM, Kong V, Malkiewicz I, Mazulli T, Moussa G, Cohen LB. Drug-induced severe adverse reaction enhanced by human herpes virus-6 reactivation. *Transl Res.*; 161(5):430-40, 2013.

Nobrega JN

Nona CN, Li R, **Nobrega JN**. Altered NMDA receptor subunit gene expression in brains of mice showing high vs. low sensitization to ethanol. *Behav Brain Res.*; 260:58-66, 2013.

Mahar I, Bambico FR, Mechawar N, **Nobrega JN**. Stress, serotonin, and hippocampal neurogenesis in relation to depression and antidepressant effects. *Neurosci Biobehav Rev.*; 38:173-92, 2013.

Dubiela FP, Queiroz CM, Moreira KD, **Nobrega JN**, Sita LV, Tufik S, Hipolide DC. AMPA receptors mediate passive avoidance deficits induced by sleep deprivation. *Behav Brain Res.*; 257:189-96, 2013.

Hamani C, **Nobrega JN**. Deep brain stimulation and memory. *Expert Rev Med Devices.*; 10(4):429-31, 2013.

Aleksandrova LR, Creed MC, Fletcher PJ, Lobo DS, Hamani C, **Nobrega JN**. Deep brain stimulation of the subthalamic nucleus increases premature responding in a rat gambling task. *Behav Brain Res.*; 245:76-82, 2013.

Creed MC, **Nobrega JN**. The role of serotonin in the antidyskinetic effects of deep brain stimulation: focus on antipsychotic-induced motor symptoms. *Rev Neurosci.*; 24(2):153-66, 2013.

Nona CN, Guirguis S, **Nobrega JN**. Susceptibility to ethanol sensitization is differentially associated with changes in pCREB, trkB and BDNF mRNA expression in the mouse brain. *Behav Brain Res.*; 242:25-33, 2013.

Pushparaj A, Hamani C, Yu W, Shin DS, Kang B, **Nobrega JN**, Le Foll B. Electrical stimulation of the insular region attenuates nicotine-taking and nicotine-seeking behaviors. *Neuropsychopharmacology.*; 38(4):690-8, 2013.

Burton CL, Rizos Z, Diwan M, **Nobrega JN**, Fletcher PJ. Antagonizing 5-HT_{2A} receptors with M100907 and stimulating 5-HT_{2C} receptors with Ro60-0175 blocks cocaine-induced locomotion and zif268 mRNA expression in Sprague-Dawley rats. *Behav Brain Res.*; 240:171-81, 2013.

Creed MC, **Nobrega JN**. Neurobiological basis of dyskinetic effects induced by antipsychotics: the contribution of animal models. *Curr Med Chem.*; 20(3):389-96, 2013. Review. PubMed PMID: 23157631.

Creed MC, Hamani C, **Nobrega JN**. Effects of repeated deep brain stimulation on depressive- and anxiety-like behavior in rats: comparing entopeduncular and subthalamic nuclei. *Brain Stimul.*; 6(4):506-14, 2013.

Pinho N, Moreira KM, Hipolide DC, Sinigaglia-Coimbra R, Ferreira TL, **Nobrega JN**, Tufik S, Oliveira MG. Sleep deprivation alters phosphorylated CREB levels in the amygdala: relationship with performance in a fear conditioning task. *Behav Brain Res.*; 236(1):221-4, 2013.

O'Brien PJ

MacAllister SL, Young C, Guzdek A, Zhidkov N, **O'Brien PJ**. Molecular cytotoxic mechanisms of chlorpromazine in isolated rat hepatocytes. *Can J Physiol Pharmacol.*; 91(1):56-63, 2013.

MacAllister SL, Martin-Brisac N, Lau V, Yang K, **O'Brien PJ**. Acrolein and chloroacetaldehyde: an examination of the cell and cell-free biomarkers of toxicity. *Chem Biol Interact.*; 202(1-3):259-66, 2013.

Lip H, Yang K, MacAllister SL, **O'Brien PJ**. Glyoxal and methylglyoxal: autoxidation from dihydroxyacetone and polyphenol cytoprotective antioxidant mechanisms. *Chem Biol Interact.*; 202(1-3):267-74, 2013.

MacAllister SL, Maruf AA, Wan L, Chung E, **O'Brien P**. Modeling xenobiotic susceptibility to hepatotoxicity using an in vitro oxidative stress inflammation model. *Can J Physiol Pharmacol.*; 91(3):236-40, 2013.

O'Dowd BF

Kabli N, Nguyen T, Balboni G, **O'Dowd BF**, George SR. Antidepressant-like and anxiolytic-like effects following activation of the μ - δ opioid receptor heteromer in the nucleus accumbens. *Mol Psychiatry*. 2013 Sep 24. doi: 10.1038/mp.2013.115. [Epub ahead of print]

Perreault ML, Fan T, **O'Dowd BF**, George SR. Enhanced brain-derived neurotrophic factor signaling in the nucleus accumbens of juvenile rats. *Dev Neurosci.*; 35(5):384-95, 2013.

Perreault ML, Hasbi A, **O'Dowd BF**, George SR. Heteromeric dopamine receptor signaling complexes: emerging neurobiology and disease relevance. *Neuropsychopharmacology.*; 39(1):156-68, 2013.

O'Dowd BF, Nguyen T, Ji X, George SR. D5 dopamine receptor carboxyl tail involved in D5-D2 heteromer formation. *Biochem Biophys Res Commun.*; 431(3):586-9, 2013.

Novak G, Fan T, **O'Dowd BF**, George SR. Postnatal maternal deprivation and pubertal stress have additive effects on dopamine D2 receptor and CaMKII beta expression in the striatum. *Int J Dev Neurosci.*; 31(3):189-95, 2013.

Novak G, Fan T, **O'Dowd BF**, George SR. Striatal development involves a switch in gene expression networks, followed by a myelination event: implications for neuropsychiatric disease. *Synapse.*; 67(4):179-88, 2013.

Perreault ML, Jones-Tabah J, O'Dowd BF, George SR. A physiological role for the dopamine D5 receptor as a regulator of BDNF and Akt signalling in rodent prefrontal cortex. *Int J Neuropsychopharmacol.*; 16(2):477-83, 2013.

Okey AB

Watson JD, Prokopec SD, Smith AB, **Okey AB**, Pohjanvirta R, Boutros PC. TCDD dysregulation of 13 AHR-target genes in rat liver. *Toxicol Appl Pharmacol.*; 274(3):445-54, 2013.

Prokopec SD, Watson JD, Waggott DM, Smith AB, Wu AH, **Okey AB**, Pohjanvirta R, Boutros PC. Systematic evaluation of medium-throughput mRNA abundance platforms. *RNA.*; 19(1):51-62, 2013.

Pace-Asciak CR

Masood A, Yi M, Lau M, Belcastro R, Li J, Kantores C, **Pace-Asciak CR**, Jankov RP, Tanswell AK. Cyclooxygenase-2 inhibition partially protects against 60% O₂-mediated lung injury in neonatal rats. *Pediatr Pulmonol.* 2013 Nov 23. doi: 10.1002/ppul.22921. [Epub ahead of print]

Pace-Asciak CR, Li X, Reynaud D, Qiao N, Demin P, Abdelhaleem M. Alterations in eicosanoid levels during U937 bcl-xL tumour growth suppression and recovery in NU/NU mice in vivo-Involvement of phospholipase A2. *Prostaglandins Other Lipid Mediat.*; 107:43-7, 2013.

Bosco N, Brahmhatt V, Oliveira M, Martin FP, Lichti P, Raymond F, Mansourian R, Metairon S, **Pace-Asciak CR**, Bastic Schmid V, Rezzi S, Haller D, Benyacoub J. Effects of increase in fish oil intake on intestinal eicosanoids and inflammation in a mouse model of colitis. *Lipids Health Dis.*; 12(1):81, 2013.

Brahmbhatt V, Oliveira M, Briand M, Perrisseau G, Bastic Schmid V, Destailats F, **Pace-Asciak CR**, Benyacoub J, Bosco N. Protective effects of dietary EPA and DHA on ischemia-reperfusion-induced intestinal stress. *J Nutr Biochem.*; 24(1):104-11, 2013.

Pang KS

Chow EC, Quach HP, Vieth R, **Pang KS**. Temporal changes in tissue $1\alpha,25$ -dihydroxyvitamin D₃, vitamin D receptor target genes, and calcium and PTH levels after $1,25(\text{OH})_2\text{D}_3$ treatment in mice. *Am J Physiol Endocrinol Metab.*; 304(9):E977-89, 2013.

Chow EC, **Pang KS**. Why we need proper PBPK models to examine intestine and liver oral drug absorption. *Curr Drug Metab.*; 14(1):57-79, 2013.

Chow EC, Magomedova L, Quach HP, Patel RH, Durk MR, Fan J, Maeng HJ, Irondi K, Anakk S, Moore DD, Cummins CL, **Pang KS**. Vitamin D Receptor Activation Down-Regulates Small

Heterodimer Partner and Increases CYP7A1 to Lower Cholesterol. *Gastroenterology.*; 21. pii: S0016-5085(13)01840-4, 2013.

Chow EC, Durk MR, Maeng HJ, **Pang KS**. Comparative effects of 1α -hydroxyvitamin D₃ and $1,25$ -dihydroxyvitamin D₃ on transporters and enzymes in *fxr*(+/+) and *fxr*(-/-) mice. *Biopharm Drug Dispos.*; 34(7):402-16, 2013.

Park H-W

Li B, Tempel W, Smil D, Bolshan Y, Schapira M, **Park HW**. Crystal structures of *Klebsiella pneumoniae* pantothenate kinase in complex with N-substituted pantothenamides. *Proteins*, 8:1466-1472, 2013.

Strushkevich N, Gilep AA, Shen L, Arrowsmith CH, Edwards AM, Usanov SA, **Park HW**. Structural insights into aldosterone synthase substrate specificity and targeted inhibition. *Mol Endocrinol*, 27: 315-324, 2013.

Tempel W, Dimov S, Tong Y, **Park HW**, Hong BS. Crystal structure of human multiple copies in T cell lymphoma-1 oncoprotein. *Proteins*, 81: 519-525, 2013.

Parker JD

Goeree R, Blackhouse G, Bowen JM, O'Reilly D, Sutherland S, Hopkins R, Chow B, Freeman M, Provost Y, Dennie C, Cohen E, Marcuzzi D, Iwanochko R, Moody A, Paul N, **Parker JD**. Cost-effectiveness of 64-slice CT angiography compared to conventional coronary angiography based on a coverage with evidence development study in Ontario. *Expert Rev Pharmacoecon Outcomes Res.*; 13(5):675-90, 2013.

Chan W, Woldeyohannes M, Colman R, Arand P, Michaels AD, **Parker JD**, Granton JT, Mak S. Haemodynamic and structural correlates of the first and second heart sounds in pulmonary arterial hypertension: an acoustic cardiography cohort study. *BMJ Open.*; 3(4). pii: e002660, 2013.

Luca MC, Liuni A, McLaughlin K, Gori T, **Parker JD**. Daily ischemic preconditioning provides sustained protection from ischemia-reperfusion induced endothelial dysfunction: a human study. *J Am Heart Assoc.*; 2(1):e000075, 2013.

Jedrzekiewicz S, **Parker JD**. Acute and chronic effects of glyceryl trinitrate therapy on insulin and glucose regulation in humans. *J Cardiovasc Pharmacol Ther.*; 18(3):211-6, 2013.

Lisi M, Dragoni S, Leone MC, Münzel T, **Parker JD**, Gori T. Acute (but not chronic) smoking paradoxically protects the endothelium from ischemia and reperfusion: insight into the "smoking paradox". *Clin Res Cardiol.*; 102(5):387-9, 2013.

Pennefather P

Phillips K, Kohler JC, **Pennefather P**, Thorsteinsdottir H, Wong J. Canada's neglected tropical disease research network: who's in the core-who's on the periphery? *PLoS Negl Trop Dis.*; 7(12):e2568, 2013.

Petronis A

Prokopec SD, Buchner NB, Fox NS, Chong LC, Mak DY, Watson JD, **Petronis A**, Pohjanvirta R, Boutros PC. Validating reference genes within a mouse model system of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) toxicity. *Chem Biol Interact.*; 205(1):63-71, 2013.

Kriukienė E, Labrie V, Khare T, Urbanavičiūtė G, Lapinaitė A, Koncvičius K, Li D, Wang T, Pai S, Ptak C, Gordevičius J, Wang SC, **Petronis A**, Klimašauskas S. DNA unmethylome profiling by covalent capture of CpG sites. *Nat Commun.*; 4:2190, 2013.

Piquette-Miller M

Cressman AM, McDonald CR, Silver KL, Kain KC, **Piquette-Miller M**. Malaria Infection Alters the Expression of Hepatobiliary and Placental Drug Transporters in Pregnant Mice. *Drug Metab Dispos.* 2013 Nov 26. [Epub ahead of print]

Chen JY, **Piquette-Miller M**, Smith BP. Network medicine: finding the links to personalized therapy. *Clin Pharmacol Ther.*; 94(6):613-6, 2013.

Zhidkov N, De Souza R, Ghassemi AH, Allen C, **Piquette-Miller M**. Continuous intraperitoneal Carboplatin delivery for the treatment of late-stage ovarian cancer. *Mol Pharm.*; 10(9):3315-22, 2013.

Pollock BG

Takeuchi H, Suzuki T, Bies RR, Remington G, Mamo DC, **Pollock BG**, Mimura M, Uchida H. Estimated Dopamine D2 Receptor Occupancy from Plasma Concentrations of Atypical Antipsychotics and Subjective Experience/Drug Attitude in Schizophrenia: An Analysis of the CATIE Data. *Schizophrenia Research.*; 150:373-9, 2013.

Sakurai, H, Uchida H, Abe T, Nakajima S, Suzuki T, **Pollock BG**, Sato Y, Mimura M. Trajectories of Individual Symptoms in Remitters versus Non-Remitters with Depression. *J Affect Disord.* ;151:506-13, 2013.

Day GS, Farb NAS, Tang-Wai DF, Masellis M, Black SE, Freedman M, **Pollock BG**, Chow TW. Salience Network Resting-State Activity: Prediction of Frontotemporal Dementia Progression. *JAMA Neurology.*; 70:1249-1253, 2013.

Gerretsen P, Mulsant B, Liu A, Granholm E, Menon M, **Pollock BG**, Mamo D, Rajji T. Insight into Illness in Late-Life Schizophrenia: A Function of Illness Severity and Premorbid Intellectual Function. *Schizophrenia Research.*; 150:217-222, 2013.

Moriguchi S, Bies RR, Remington G, Suzuki T, Mamo DC, Watanabe K, Mimura M, **Pollock BG**, Uchida H. Estimated Dopamine D2 Receptor Occupancy and Remission in Schizophrenia: Analysis of the CATIE Data. *J Clin Psychopharm.*; 33:682-85, 2013.

Voineskos AN, Felsky D, Kovacevic N, Tiwari AK, Zai CC, Chakravarty MM, Lobaugh NJ, Shenton ME, Rajji TK, Miranda D, **Pollock BG**, Mulsant BH, McIntosh AR, Kennedy JL. Oligodendrocyte genes, white matter tract integrity and cognition in schizophrenia. *Cerebral Cortex.*; 23:2044-57, 2013.

Tsuboi T, Bies RR, Suzuki T, Mamo DC, **Pollock BG**, Graff-Guerrero A, Mimura M, Uchida H. Hyperprolactinemia and Estimated Dopamine D2 Receptor Occupancy and in Patients with Schizophrenia: Analysis of the CATIE Data. *Prog in Neuro-Psychopharmacology & Biological Psychiatry*; 45:178-82, 2013.

Nakajima S, Gerretsen P, Takeuchi H, Caravaggio F, Chow TW, LeFoll B, Mulsant B, **Pollock BG**, Graff-Guerrero A. The Potential Role of Dopamine D3 Receptor Neurotransmission in Cognition. *European Neuropsychopharmacology.*; 23:799-813, 2013.

Suzuki T, Graff-Guerrero A, Uchida H, Remington G, Caravaggio F, Borlido C, **Pollock BG**, Mulsant B, DeLuca V, Ismail Z, Mamo D. Dopamine D2/3 occupancy of ziprasidone across a day: a within-subject PET study. *Psychopharmacology.*; 228:43-51, 2013.

Farb NAS, Grady C, Strother S, Tang-Wai D, Masellis M, Black S, Freedman M, **Pollock BG**, Campbell K, Hasher L, Chow T. Abnormal network connectivity in frontotemporal dementia: Evidence for prefrontal isolation. *Cortex.*; 49:1856-1873, 2013.

Links KA, Black SE, Graff-Guerrero A, Wilson AA, Houle S, **Pollock BG**, Chow TC. A case of apathy due to frontotemporal dementia responsive to memantine. *Neurocase.*; 19:256-61, 2013.

Quilty L, Ayhearst L, Chmielewski M, **Pollock BG**, Bagby RM. The Psychometric Properties of the Personality Inventory for DSM-5 (PID-5) in an APA DSM-5 Field Trial Sample. *Assessment.*; 20:362-9, 2013.

Sakurai H, Bies RR, Stroup S, Keefe RSE, Rajji TK, Suzuki T, Mamo DC, **Pollock BG**, Watanabe K, Mimura M, Uchida H. Dopamine D2 receptor occupancy and cognition in schizophrenia: Analysis of the CATIE data. *Schizphr Bull.*; 35:564-74, 2013.

Gerretsen P, Chakravarty MM, Mamo D, Menon M, **Pollock BG**, Rajji TK, Graff-Guerrero A. Frontotemporoparietal asymmetry and lack of illness awareness in Schizophrenia. *Human Brain Mapping.*; 34:1035-43, 2013.

Voineskos A, Foussias G, Lerch J, Felsky D, Remington G, Rajji T, Lobaugh N, **Pollock BG**, Mulsant B. Neuroimaging Evidence for the Schizophrenia Deficit Subtype. *JAMA Psychiatry.*; 70:472-80, 2013.

Gerretsen P, **Pollock BG**. Cognitive risks of anticholinergics in the elderly. *Aging Health.*; 9:159-66, 2013.

Lenze EJ, Lotrich FE, Nowotny P, **Pollock BG**, Dixon D, Dore PM, Hinrichs AL, Butters MA. Escitalopram reduces attentional performance in anxious older adults with high-expression genetic variants at serotonin 2A and 1B receptors. *Int J Neuropsychopharmacol.*; 16:279-88, 2013.

Chow TW, Fam D, Graff-Guerrero A, Verhoeff NPG, Tang-Wai DF, Masellis M, Black SE, Wilson AA, Houle S, **Pollock BG**. Fluodeoxyglucose positron emission tomography (FDG-PET) in semantic dementia after 6 months of memantine: An open-label pilot study. *Int J Geriatr Psychiatry.*; 28:319-25, 2013.

Li CH, **Pollock BG**, Lyketsos CG, Vaidya V, Drye LT, Kirshner M, Sorisio D, Bies RR, for the DIADS-2 Research Group. Population pharmacokinetic modeling of sertraline treatment in Alzheimer's Disease patients: The DIADS-2 study. *J Clin Pharmacol.*; 53:234-9, 2013.

Ismail Z, Chetachi A, Emeremni C, Houck PR, Mazumdar S, Rosen J, Rajji TR, **Pollock BG**, Mulsant BH. A comparison of the E-BEHAVE-AD, NBRIS and NPI in quantifying clinical improvement in the treatment of agitation and psychosis associated with dementia. *American Journal of Geriatric Psychiatry.*; 21:78-87, 2013.

Ramsey AJ

Medvedev IO, **Ramsey AJ**, Masoud ST, Bermejo MK, Urs N, Sotnikova TD, Beaulieu JM, Gainetdinov RR, Salahpour A. D1 dopamine receptor coupling to PLC β 2 regulates forward locomotion in mice. *J Neurosci.*; 33(46):18125-33, 2013.

Ramsey AJ, Gregory KJ, Herman EJ, Hammond AS, Byun NE, Stauffer SR, Manka JT, Jadhav S, Bridges TM, Weaver CD, Niswender CM, Steckler T, Drinkenburg WH, Ahnaou A, Lavreysen H, Macdonald GJ, Bartolom   JM, Mackie C, Hrupka BJ, Caron MG, Daigle TL, Lindsley CW, Conn PJ, Jones CK. N-aryl piperazine metabotropic glutamate receptor 5 positive allosteric modulators possess efficacy in preclinical models of NMDA hypofunction and cognitive enhancement. *J Pharmacol Exp Ther.*; 347(2):438-57, 2013.

Siesser WB, Sachs BD, **Ramsey AJ**, Sotnikova TD, Beaulieu JM, Zhang X, Caron MG, Gainetdinov RR. Chronic SSRI treatment exacerbates serotonin deficiency in humanized Tph2 mutant mice. *ACS Chem Neurosci.*; 4(1):84-8, 2013.

Riddick DS

Lee C, Mullen Grey AK, **Riddick DS**. Loss of hepatic aryl hydrocarbon receptor protein in adrenalectomized rats does not involve altered levels of the receptor's cytoplasmic chaperones. *Can J Physiol Pharmacol.*; 91(12):1154-7, 2013.

Lee C, Ding X, **Riddick DS**. Downregulation of mouse hepatic CYP3A protein by 3-methylcholanthrene does not require cytochrome P450-dependent metabolism. *Drug Metab Dispos.*; 41(10):1782-6, 2013.

Lee C, Ding X, **Riddick DS**. The role of cytochrome P450-dependent metabolism in the regulation of mouse hepatic growth hormone signaling components and target genes by 3-methylcholanthrene. *Drug Metab Dispos.*; 41(2):457-65, 2013.

Wu AM, Dalvi P, Lu X, Yang M, **Riddick DS**, Matthews J, Clevenger CV, Ross DD, Harper PA, Ito S. Induction of multidrug resistance transporter ABCG2 by prolactin in human breast cancer cells. *Mol Pharmacol.*; 83(2):377-88, 2013.

Riddick DS, Ding X, Wolf CR, Porter TD, Pandey AV, Zhang QY, Gu J, Finn RD, Ronseaux S, McLaughlin LA, Henderson CJ, Zou L, Flück CE. NADPH-cytochrome P450 oxidoreductase: roles in physiology, pharmacology, and toxicology. *Drug Metab Dispos.*; 41(1):12-23, 2013.

Ross RA

Imbernon M, Whyte L, Diaz-Arteaga A, Russell WR, Moreno NR, Vazquez MJ, Gonzalez CR, Díaz-Ruiz A, Lopez M, Malagón MM, **Ross RA**, Dieguez C, Nogueiras R. Regulation of GPR55 in rat white adipose tissue and serum LPI by nutritional status, gestation, gender and pituitary factors. *Mol Cell Endocrinol.*; 5 383(1-2):159-69, 2013.

Shore DM, Ballie GL, Hurst DP, Navas FJ 3rd, Seltzman HH, Marcu JP, Abood ME, **Ross RA**, Reggio PH. Allosteric Modulation of a Cannabinoid G Protein-Coupled Receptor: Binding Site Elucidation and Relationship to G Protein Signaling. *J. Biol Chem.* 2013 Dec 23. [Epub ahead of print]

Marini P, Cascio MG, King A, Pertwee RG, **Ross RA**. Characterization of cannabinoid receptor ligands in tissues natively expressing cannabinoid CB2 receptors. *Br J Pharmacol.*; 169(4):887-99, 2013.

Sylantsev S, Jensen TP, **Ross RA**, Rusakov DA. Cannabinoid- and lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter release at central synapses. *Proc Natl Acad Sci U S A.*; 26 110(13):5193-8, 2013.

Baillie GL, Horswill JG, Anavi-Goffer S, Reggio PH, Bolognini D, Abood ME, McAllister S, Strange PG, Stephens GJ, Pertwee RG, **Ross RA**. CB(1) receptor allosteric modulators display both agonist and signaling pathway specificity. *Mol Pharmacol.*; 83(2):322-38, 2013.

Salahpour A

Lam VM, Beerepoot P, Angers S, **Salahpour A**. A novel assay for measurement of membrane-protein surface expression using a β -lactamase. *Traffic.*; 14(7):778-84, 2013.

Calipari ES, Ferris MJ, **Salahpour A**, Caron MG, Jones SR. Methylphenidate amplifies the potency and reinforcing effects of amphetamines by increasing dopamine transporter expression. *Nat Commun.*; 4:2720, 2013.

Beerepoot P, Lam VM, **Salahpour A**. Measurement of G protein-coupled receptor surface expression. *J Recept Signal Transduct Res.*; 33(3):162-5, 2013.

Medvedev IO, Ramsey AJ, Masoud ST, Bermejo MK, Urs N, Sotnikova TD, Beaulieu JM, Gainetdinov RR, **Salahpour A**. D1 dopamine receptor coupling to PLC β regulates forward locomotion in mice. *J Neurosci.*; 33(46):18125-33, 2013.

Salmena L

Lunardi A, Ala U, Epping MT, **Salmena L**, Clohessy JG, Webster KA, Wang G, Mazzucchelli R, Bianconi M, Stack EC, Lis R, Patnaik A, Cantley LC, Bublely G, Cordon-Cardo C, Gerald WL, Montironi R, Signoretti S, Loda M, Nardella C, Pandolfi PP. A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. *Nat Genet.*; 45(7):747-55, 2013.

Salmena L, Hakem R. From photomorphogenesis to cancer: a CSN journey. *Cell Cycle.*;12(2):205-6, 2013.

Schapira M

Yu W, Smil D, Li F, Tempel W, Fedorov O, Nguyen KT, Bolshan Y, Al-Awar R, Knapp S, Arrowsmith CH, Vedadi M, Brown PJ, **Schapira M**. Bromo-deaza-SAH: a potent and selective DOT1L inhibitor. *Bioorg Med Chem.*; 21(7):1787-94, 2013.

Nguyen KT, Li F, Poda G, Smil D, Vedadi M, **Schapira M**. Strategy to Target the Substrate Binding site of SET Domain Protein Methyltransferases. *J Chem Inf Model.*; 53(3):681-91, 2013.

Senisterra G, Wu H, Allali-Hassani A, Wasney GA, Baryte-Lovejoy D, Dombrovski L, Dong A, Nguyen KT, Smil D, Bolshan Y, Hajian T, He H, Seitova A, Chau I, Li F, Poda G, Couture JF, Brown PJ, Al-Awar R, **Schapira M**, Arrowsmith CH, Vedadi M. Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5. *Biochem J.*; 449(1):151-9, 2013.

Wu H, Siarheyeva A, Zeng H, Lam R, Dong A, Wu XH, Li Y, **Schapira M**, Vedadi M, Min J. Crystal structures of the human histone H4K20 methyltransferases SUV420H1 and SUV420H2. *FEBS Lett.* pii: S0014-5793(13)00777-1, 2013. [Epub ahead of print]

Wu H, Zeng H, Dong A, Li F, He H, Senisterra G, Seitova A, Duan S, Brown PJ, Vedadi M, Arrowsmith CH, **Schapira M**. Structure of the Catalytic Domain of EZH2 Reveals Conformational Plasticity in Cofactor and Substrate Binding Sites and Explains Oncogenic Mutations. *PLoS One.*; 8(12):e83737, 2013.

Shah MA, Denton EL, Liu L, **Schapira M**. ChromoHub V2: cancer genomics. *Bioinformatics.*; 30(4):590-2, 2013.

Li B, Tempel W, Smil D, Bolshan Y, **Schapira M**, Park HW. Crystal structures of *Klebsiella pneumoniae* pantothenate kinase in complex with N-substituted pantothenamides. *Proteins.*; 81(8):1466-72, 2013.

Liu F, Li F, Ma A, Dobrovetsky E, Dong A, Gao C, Korboukh I, Liu J, Smil D, Brown PJ, Frye SV, Arrowsmith CH, **Schapira M**, Vedadi M, Jin J. Exploiting an allosteric binding site of PRMT3 yields potent and selective inhibitors. *J Med Chem.*; 56(5):2110-24, 2013.

Bolshan Y, Getlik M, Kuznetsova E, Wasney G, Hajian T, Poda G, Nguyen K, Wu H, Dombrowski L, Dong A, **Schapira M**, Arrowsmith C, Brown P, Al-awar R, Vedadi M, Smil D. "Synthesis, Optimization, and Evaluation of Novel Small Molecules as Antagonists of WDR5-MLL Interaction." *ACS Medicinal Chemistry Letters.*, 4(3): 353-357, 2013.

Schimmer BP

Schimmer BP. Preface: Fifteenth conference on the adrenal cortex (adrenal 2012) League City, Texas June 19-22, 2012. *Mol Cell Endocrinol.*; 371(1-2):1, 2013.

Seeman P

Koprach JB, Huot P, Fox SH, Jarvie K, Lang AE, **Seeman P**, Brotchie JM. The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques. *Prog Neuropsychopharmacol Biol Psychiatry.*; 43:151-6, 2013.

Seeman P. Comment on: "Adverse events in healthy subjects exposed to single and multiple doses of LY2140023 monohydrate" by Ayan-Oshodi et al (*J Clin Psychopharmacol* 2012;32[3]:408-411). *J Clin Psychopharmacol.*; 33(2):280, 2013.

Seeman P, Tinazzi M. Loss of dopamine neuron terminals in antipsychotic-treated schizophrenia; relation to tardive dyskinesia. *Prog Neuropsychopharmacol Biol Psychiatry.*; 44:178-83, 2013.

Seeman P. Clozapine, a fast-off-d2 antipsychotic. *ACS Chem Neurosci.*; 5(1):24-9, 2013.

Seeman MV, **Seeman P**. Is schizophrenia a dopamine supersensitivity psychotic reaction? *Prog Neuropsychopharmacol Biol Psychiatry.*; 48:155-60, 2013.

Seeman P. Schizophrenia thalamus imaging: low benzamide binding to dopamine D2 receptors suggests fewer D2Short receptors and fewer presynaptic terminals. *Psychiatry Res.*; 214(3):175-80, 2013.

Seeman P. An agonist at glutamate and dopamine D2 receptors, LY404039. *Neuropharmacology.*; 66:87-8, 2013.

Seeman P. Schizophrenia and dopamine receptors. *Eur Neuropsychopharmacol.*; 23(9):999-1009, 2013.

Seeman P. Are dopamine D2 receptors out of control in psychosis? *Prog Neuropsychopharmacol Biol Psychiatry.*; 46:146-52, 2013.

Semple JW

Guo L, Yang L, Speck ER, Aslam R, Kim M, McKenzie CG, Lazarus AH, Ni H, Hou M, Freedman J, **Semple JW.** Allogeneic platelet transfusions prevent murine T-cell-mediated immune thrombocytopenia. *Blood.*; 123(3):422-7, 2013.

McKenzie CG, Guo L, Freedman J, **Semple JW.** Cellular immune dysfunction in immune thrombocytopenia (ITP). *Br J Haematol.*; 163(1):10-23, 2013.

Semple JW. Platelets deliver small packages of genetic function. *Blood.*; 122(2):155-6, 2013.

Lazarus AH, **Semple JW,** Cines DB. Innate and adaptive immunity in immune thrombocytopenia. *Semin Hematol.*; 50 Suppl 1:S68-70, 2013.

Shear NH

Heelan K, Ryan JF, **Shear NH,** Egan CA. Wells syndrome (eosinophilic cellulitis): Proposed diagnostic criteria and a literature review of the drug-induced variant. *J Dermatol Case Rep.*; 7(4):113-20, 2013.

Amstutz U, Ross, CJD, Castro-Pastrana, LI, Rieder, MJ, **Shear NH,** Hayden MR, Carleton BC (and the Canadian Pharmacogenomics Network for Drug Safety Consortium) HLA-B15:02 and HLA-A 31:01 as genetic markers for carbamazepine hypersensitivity in children. *Clin Pharmacol Ther* 2013; **epub:** doi:10.1038/clpt.2013.55.

Chan BC, Seung SJ, McLean D, Bell M, **Shear NH,** Mittmann N. Etanercept patient assistance program: another data source for epidemiologic studies? *Adv Pharmacoepidemiology Drug Safety* 2013: in press.

Papp K, Guenther L, **Shear NH,** Binder C, Tan J, Lynde C, Gulliver W, Stang P. Understanding and assessing potential serious adverse events: A practical approach to understanding the benefits and harm of psoriasis treatments. *J Cutan Med Surg*; 17: 189-96, 2013.

Bailey K, Mckee D, Wismer J, **Shear NH**. Acute generalized exanthematous pustulosis induced by hydroxychlorquine: First case report in Canada and review of the literature. *J Cutan Med Surg*; 17(6): 414-8, 2013.

Heelan K, Knowles S, Walsh S, **Shear NH**. Effect of concomitant statin use on rituximab treatment for pemphigus and pemphigoid disorders: a case-based review. *J Eur Acad Dermatol Venereol.*: 10.1111/jdv.12217, 2013. [Epub ahead of print]

Heelan K, Walsh S, **Shear NH**. Treatment of mucous membrane pemphigoid with rituximab. *J Am Acad Dermatol.*; 69(2):310-1, 2013.

Heelan K, **Shear NH**. Cutaneous drug reactions in children: an update. *Paediatr Drugs.*; 15(6):493-503, 2013.

Jakubovic BD, Donovan A, Webster PM, **Shear NH**. Methotrexate-induced pulmonary toxicity. *Can Respir J.*; 20(3):153-5, 2013.

Alhusayen RO, Juurlink DN, Mamdani MM, Morrow RL, **Shear NH**, Dormuth CR; Canadian Drug Safety and Effectiveness Research Network. Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study. *J Invest Dermatol.*; 133(4):907-12, 2013.

Shram MJ

Zou S, Funk D, **Shram MJ**, Lê AD. Effects of stressors on the reinforcing efficacy of nicotine in adolescent and adult rats. *Psychopharmacology (Berl)*. 2013 Oct 25. [Epub ahead of print] PubMed PMID: 24510175.

Harris SC, Perrino PJ, Smith I, **Shram MJ**, Colucci SV, Bartlett C, Sellers EM. Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users. *J Clin Pharmacol*. 2013 Nov 16. doi: 10.1002/jcph.235. [Epub ahead of print]

Setnik B, Goli V, Levy-Cooperman N, Mills C, **Shram MJ**, Smith I. Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. *Pain Res Manag.*; 18(4):e55-62, 2013.

Sun HS

Bae CY, **Sun HS**. Current understanding of TRPM7 pharmacology and drug development for stroke. *Acta Pharmacol Sin.*; 34(1):10-6, 2013.

Sun HS, Feng ZP. Neuroprotective role of ATP-sensitive potassium channels in cerebral ischemia. *Acta Pharmacol Sin.*; 34(1):24-32, 2013.

Alibrahim A, Zhao LY, Bae CY, Barszczyk A, Sun CL, Wang GL, **Sun HS**. Neuroprotective effects of volume-regulated anion channel blocker DCPIB on neonatal hypoxic-ischemic injury. *Acta Pharmacol Sin.*; 34(1):113-8, 2013.

Instrum R, **Sun HS**. Restoring neuroprotection through a new preclinical paradigm: translational success for NA-1 in stroke therapy. *Acta Pharmacol Sin.*; 34(1):3-5, 2013.

Sun HS. Current mechanisms in stroke. *Acta Pharmacol Sin.*; 34(1):1-2, 2013.

Tong Y

Tempel W, Dimov S, **Tong Y**, Park HW, Hong BS. Crystal structure of human multiple copies in T-cell lymphoma-1 oncoprotein. *Proteins.*; 81(3):519-25, 2013.

Tyndale RF (33)

David SP, Strong DR, Leventhal AM, Lancaster MA, McGeary JE, Munafò MR, Bergen AW, Swan GE, Benowitz NL, **Tyndale RF**, Conti DV, Brown RA, Lerman C, Niaura R. Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion. *Addiction.*; 108(12):2202-11, 2013.

Zhu AZ, Zhou Q, Cox LS, Ahluwalia JS, Benowitz NL, **Tyndale RF**. Variation in trans-3'-hydroxycotinine glucuronidation does not alter the nicotine metabolite ratio or nicotine intake. *PLoS One.*; 8(8):e70938, 2013.

Dempsey DA, St Helen G, Jacob P 3rd, **Tyndale RF**, Benowitz NL. Genetic and pharmacokinetic determinants of response to transdermal nicotine in white, black, and Asian nonsmokers. *Clin Pharmacol Ther.*; 94(6):687-94, 2013.

Ogawa S, Surapisitchat J, Virtanen C, Ogawa M, Niapour M, Sugamori KS, Wang S, Tamblyn L, Guillemette C, Hoffmann E, Zhao B, Strom S, Laposa RR, **Tyndale RF**, Grant DM, Keller G. Three-dimensional culture and cAMP signaling promote the maturation of human pluripotent stem cell-derived hepatocytes. *Development.*; 140(15):3285-96, 2013.

Falcone M, Smith RM, Chenoweth MJ, Kumar Bhattacharjee A, Kelsoe JR, **Tyndale RF**, Lerman C; Pharmacogenomics Research Network Central Nervous System Working Group. Neuroimaging in psychiatric pharmacogenetics research: the promise and pitfalls. *Neuropsychopharmacology.*; 38(12):2327-37, 2013.

Dempsey DA, Sambol NC, Jacob P 3rd, Hoffmann E, **Tyndale RF**, Fuentes-Afflick E, Benowitz NL. CYP2A6 genotype but not age determines cotinine half-life in infants and children. *Clin Pharmacol Ther.*; 94(3):400-6, 2013.

Zhu AZ, Renner CC, Hatsukami DK, Benowitz NL, **Tyndale RF**. CHRNA5-A3-B4 genetic variants alter nicotine intake and interact with tobacco use to influence body weight in Alaska Native tobacco users. *Addiction.*; 108(10):1818-28, 2013.

Ferguson CS, Miksys S, Palmour RM, **Tyndale RF**. Ethanol self-administration and nicotine treatment induce brain levels of CYP2B6 and CYP2E1 in African green monkeys. *Neuropharmacology*.; 72:74-81, 2013.

Zhou K, Khokhar JY, Zhao B, **Tyndale RF**. First demonstration that brain CYP2D-mediated opiate metabolic activation alters analgesia in vivo. *Biochem Pharmacol*.; 85(12):1848-55, 2013.
Cheng J, Zhen Y, Miksys S, Beyoğlu D, Krausz KW, **Tyndale RF**, Yu A, Idle JR, Gonzalez FJ. Potential role of CYP2D6 in the central nervous system. *Xenobiotica*. ; 43(11):973-84, 2013.

Wassenaar CA, Dong Q, Amos CI, Spitz MR, **Tyndale RF**. Pilot Study of CYP2B6 Genetic Variation to Explore the Contribution of Nitrosamine Activation to Lung Carcinogenesis. *Int J Mol Sci*.; 14(4):8381-92, 2013.

Bough KJ, Lerman C, Rose JE, McClernon FJ, Kenny PJ, **Tyndale RF**, David SP, Stein EA, Uhl GR, Conti DV, Green C, Amur S. Biomarkers for smoking cessation. *Clin Pharmacol Ther*.; 93(6):526-38, 2013.

Miksys S, Cappendijk SL, Perry WM, Zhao B, **Tyndale RF**. Nicotine kinetics in zebra finches in vivo and in vitro. *Drug Metab Dispos*.; 41(6):1240-6, 2013.

Chenoweth MJ, O'Loughlin J, Sylvestre MP, **Tyndale RF**. CYP2A6 slow nicotine metabolism is associated with increased quitting by adolescent smokers. *Pharmacogenet Genomics*.; 23(4):232-5, 2013.

Esterlis I, Hannestad JO, Perkins E, Bois F, D'Souza DC, **Tyndale RF**, Seibyl JP, Hatsukami DM, Cosgrove KP, O'Malley SS. Effect of a nicotine vaccine on nicotine binding to $\beta 2^*$ -nicotinic acetylcholine receptors in vivo in human tobacco smokers. *Am J Psychiatry*.; 170(4):399-407, 2013.

Zhu AZ, Renner CC, Hatsukami DK, Swan GE, Lerman C, Benowitz NL, **Tyndale RF**. The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race, and sex. *Cancer Epidemiol Biomarkers Prev*.; 22(4):708-18, 2013.

Sellings L, Pereira S, Qian C, Dixon-McDougall T, Nowak C, Zhao B, **Tyndale RF**, van der Kooy D. Nicotine-motivated behavior in *Caenorhabditis elegans* requires the nicotinic acetylcholine receptor subunits *acr-5* and *acr-15*. *Eur J Neurosci*.; 37(5):743-56, 2013.

Ting-A-Kee R, Vargas-Perez H, Bufalino MR, Bahi A, Dreyer JL, **Tyndale RF**, van der Kooy D. Infusion of brain-derived neurotrophic factor into the ventral tegmental area switches the substrates mediating ethanol motivation. *Eur J Neurosci*.; 37(6):996-1003, 2013.

Miksys S, **Tyndale RF**. Cytochrome P450-mediated drug metabolism in the brain. *J Psychiatry Neurosci*.; 38(3):152-63, 2013.

Zhu AZ, Binnington MJ, Renner CC, Lanier AP, Hatsukami DK, Stepanov I, Watson CH, Sosnoff CS, Benowitz NL, **Tyndale RF**. Alaska Native smokers and smokeless tobacco users with slower CYP2A6 activity have lower tobacco consumption, lower tobacco-specific nitrosamine exposure and lower tobacco-specific nitrosamine bioactivation. *Carcinogenesis*; 34(1):93-101, 2013.

Utrecht JP

Sharma AM, Novalen M, Tanino T, **Utrecht JP**. 12-OH-nevirapine sulfate, formed in the skin, is responsible for nevirapine-induced skin rash. *Chem Res Toxicol* 26, 817-827, 2013.

Zhu X, and **Utrecht JP**. A novel T(H)17-type cell is rapidly increased in the liver in response to acetaminophen-induced liver injury: T(H)17 cells and the innate immune response. *J Immunotoxicol* 10, 287-291, 2013.

Ng W, **Utrecht JP**. Changes in gene expression induced by aromatic amine drugs: testing the danger hypothesis. *J Immunotoxicol* 10, 178-191, 2013.

Ng W, **Utrecht JP**. Effect of aminoglutethimide on neutrophils in rats: implications for idiosyncratic drug-induced blood dyscrasias. *Chem Res Toxicol* 26, 1272-1281, 2013.

Ng W, Metushi IG, **Utrecht JP**. Hepatic effects of aminoglutethimide: A model aromatic amine. *J Immunotoxicol*, 2013.

Zhang X, Sharma AM, **Utrecht JP**. Identification of danger signals in nevirapine-induced skin rash. *Chem Res Toxicol* 26, 1378-1383, 2013.

Utrecht JP, Naisbitt DJ. Idiosyncratic adverse drug reactions: current concepts. *Pharmacol Rev* 65, 779-808, 2013.

Metushi IG, **Utrecht JP**. Isoniazid-induced liver injury and immune response in mice. *J Immunotoxicol*, 2013.

Sharma AM, Klarskov K, **Utrecht JP**. Nevirapine bioactivation and covalent binding in the skin. *Chem Res Toxicol* 26, 410-421, 2013.

Vedadi M

Wu H, Siarheyeva A, Zeng H, Lam R, Dong A, Wu XH, Li Y, Schapira M, **Vedadi M**, Min J. Crystal structures of the human histone H4K20 methyltransferases SUV420H1 and SUV420H2. *FEBS Lett*. 2013 Oct 25. pii: S0014-5793(13)00777-1.

Wu H, Zeng H, Dong A, Li F, He H, Senisterra G, Seitova A, Duan S, Brown PJ, **Vedadi M**, Arrowsmith CH, Schapira M. Structure of the Catalytic Domain of EZH2 Reveals Conformational Plasticity in Cofactor and Substrate Binding Sites and Explains Oncogenic Mutations. *PLoS One*; 8(12):e83737, 2013.

Liu F, Barsyte-Lovejoy D, Li F, Xiong Y, Korboukh V, Huang XP, Allali-Hassani A, Janzen WP, Roth BL, Frye SV, Arrowsmith CH, Brown PJ, **Vedadi M**, Jin J. Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP. *J Med Chem.*; 56(21):8931-42, 2013.

Oudhoff MJ, Freeman SA, Couzens AL, Antignano F, Kuznetsova E, Min PH, Northrop JP, Lehnertz B, Barsyte-Lovejoy D, **Vedadi M**, Arrowsmith CH, Nishina H, Gold MR, Rossi FM, Gingras AC, Zaph C. Control of the hippo pathway by Set7-dependent methylation of Yap. *Dev Cell.*; 26(2):188-94, 2013.

Konze KD, Ma A, Li F, Barsyte-Lovejoy D, Parton T, Macnevin CJ, Liu F, Gao C, Huang XP, Kuznetsova E, Rougie M, Jiang A, Pattenden SG, Norris JL, James LI, Roth BL, Brown PJ, Frye SV, Arrowsmith CH, Hahn KM, Wang GG, **Vedadi M**, Jin J. An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1. *ACS Chem Biol.*; 8(6):1324-34, 2013.

Yu W, Smil D, Li F, Tempel W, Fedorov O, Nguyen KT, Bolshan Y, Al-Awar R, Knapp S, Arrowsmith CH, **Vedadi M**, Brown PJ, Schapira M. Bromo-deaza-SAH: a potent and selective DOT1L inhibitor. *Bioorg Med Chem.*; 21(7):1787-94, 2013.

Liu F, Li F, Ma A, Dobrovetsky E, Dong A, Gao C, Korboukh I, Liu J, Smil D, Brown PJ, Frye SV, Arrowsmith CH, Schapira M, **Vedadi M**, Jin J. Exploiting an allosteric binding site of PRMT3 yields potent and selective inhibitors. *J Med Chem.*; 56(5):2110-24, 2013.

Nguyen KT, Li F, Poda G, Smil D, **Vedadi M**, Schapira M. Strategy to Target the Substrate Binding site of SET Domain Protein Methyltransferases. *J Chem Inf Model.*; 53(3):681-91, 2013.

Ernst A, Avvakumov G, Tong J, Fan Y, Zhao Y, Alberts P, Persaud A, Walker JR, Neculai AM, Neculai D, Vorobyov A, Garg P, Beatty L, Chan PK, Juang YC, Landry MC, Yeh C, Zeqiraj E,

Senisterra G, Wu H, Allali-Hassani A, Wasney GA, Barsyte-Lovejoy D, Dombrovski L, Dong A, Nguyen KT, Smil D, Bolshan Y, Hajian T, He H, Seitova A, Chau I, Li F, Poda G, Couture JF, Brown PJ, Al-Awar R, Schapira M, Arrowsmith CH, **Vedadi M**. Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5. *Biochem J.*; 449(1):151-9, 2013.

Warsh JJ

Roedding AS, Tong SY, Au-Yeung W, Li PP, **Warsh JJ**. Chronic oxidative stress modulates TRPC3 and TRPM2 channel expression and function in rat primary cortical neurons: relevance to the pathophysiology of bipolar disorder. *Brain Res.*; 1517:16-27, 2013.

Xu C, **Warsh JJ**, Wang KS, Mao CX, Kennedy JL. Association of the iPLA2 β gene with bipolar disorder and assessment of its interaction with TRPM2 gene polymorphisms. *Psychiatr Genet.*; 23(2):86-9, 2013.

Wells PG

Siu MT, Wiley MJ, **Wells PG**. Methanol teratogenicity in mutant mice with deficient catalase activity and transgenic mice expressing human catalase. *Reprod Toxicol.*; 36:33-9, 2013.

Siu MT, Shapiro AM, Wiley MJ, **Wells PG**. A role for glutathione, independent of oxidative stress, in the developmental toxicity of methanol. *Toxicol Appl Pharmacol.*; 273(3):508-15, 2013.

Ramkisson A, **Wells PG**. Developmental role of nuclear factor E2-related factor 2 in mitigating methamphetamine fetal toxicity and postnatal neurodevelopmental deficits. *Free Radic Biol Med.*; 65:620-31, 2013.

Miller L, Shapiro AM, Wells PG. Embryonic catalase protects against ethanol-initiated DNA oxidation and teratogenesis in acatalasemic and transgenic human catalase-expressing mice. *Toxicol Sci*; 134(2):400-11, 2013.

Jeng W, Loniewska MM, **Wells PG**. Brain glucose-6-phosphate dehydrogenase protects against endogenous oxidative DNA damage and neurodegeneration in aged mice. *ACS Chem Neurosci.*; 4(7):1123-32, 2013.

Ondovcik SL, Preston TJ, McCallum GP, **Wells PG**. Expression of human oxoguanine glycosylase 1 or formamidopyrimidine glycosylase in human embryonic kidney 293 cells exacerbates methylmercury toxicity in vitro. *Toxicol Appl Pharmacol.*; 271(1):41-8, 2013.

Ondovcik SL, Tamblyn L, McPherson JP, **Wells PG**. Sensitivity to methylmercury toxicity is enhanced in oxoguanine glycosylase 1 knockout murine embryonic fibroblasts and is dependent on cellular proliferation capacity. *Toxicol Appl Pharmacol.*; 270(1):23-30, 2013.

Miller L, Shapiro AM, Cheng J, **Wells PG**. The free radical spin trapping agent phenylbutylnitron reduces fetal brain DNA oxidation and postnatal cognitive deficits caused by in utero exposure to a non-structurally teratogenic dose of ethanol: a role for oxidative stress. *Free Radic Biol Med.*; 60:223-32, 2013.

Wong AH

Zawadzki JA, Girard TA, Foussias G, Rodrigues A, Siddiqui I, Lerch JP, Grady C, Remington G, **Wong AH**. Simulating real world functioning in schizophrenia using a naturalistic city environment and single-trial, goal-directed navigation. *Front Behav Neurosci.*; 7:180, 2013.

Bani-Fatemi A, Gonçalves VF, Zai C, de Souza R, Le Foll B, Kennedy JL, **Wong AH**, De Luca V. Analysis of CpG SNPs in 34 genes: association test with suicide attempt in schizophrenia. *Schizophr Res.*; 147(2-3):262-8, 2013.

Lipina TV, Zai C, Hlousek D, Roder JC, **Wong AH**. Maternal immune activation during gestation interacts with Discl point mutation to exacerbate schizophrenia-related behaviors in mice. *J Neurosci.*; 33(18):7654-66, 2013.

Lee FH, Zai CC, Cordes SP, Roder JC, **Wong AH**. Abnormal interneuron development in disrupted-in-schizophrenia-1 L100P mutant mice. *Mol Brain*.; 6:20. 3013.

Ng E, McGirr A, **Wong AH**, Roder JC. Using rodents to model schizophrenia and substance use comorbidity. *Neurosci Biobehav Rev*.; 37(5):896-910, 2013.

Lipina TV, Fletcher PJ, Lee FH, **Wong AH**, Roder JC. Disrupted-in-schizophrenia-1 Gln31Leu polymorphism results in social anhedonia associated with monoaminergic imbalance and reduction of CREB and β -arrestin-1,2 in the nucleus accumbens in a mouse model of depression. *Neuropsychopharmacology*.; 38(3):423-36, 2013.

Menon M, Quilty LC, Zawadzki JA, Woodward TS, Sokolowski HM, Boon HS, **Wong AH**. The role of cognitive biases and personality variables in subclinical delusional ideation. *Cogn Neuropsychiatry*.; 18(3):208-18, 2013.

Brown C, Telio S, Warnock C, **Wong AH**. Clozapine toxicity and hepatitis, *Journal of Clinical Psychopharmacology*; 33(4):570-571, 2013.

Young LT

Huzayyin AA, Andreatza AC, Turecki G, Cruceanu C, Rouleau GA, Alda M, Young LT. Decreased global methylation in patients with bipolar disorder who respond to lithium. *Int J Neuropsychopharmacol*. 2013 Dec 17:1-9. [Epub ahead of print]

Goldstein BI, **Young LT**. Toward clinically applicable biomarkers in bipolar disorder: focus on BDNF, inflammatory markers, and endothelial function. *Curr Psychiatry Rep*.;15(12):425, 2013.

Alda M, Shao L, Wang JF, Lopez de Lara C, Jaitovich-Groisman I, Lebel V, Sun X, Duffy A, Grof P, Rouleau GA, Turecki G, **Young LT**. Alterations in phosphorylated cAMP response element-binding protein (pCREB) signaling: an endophenotype of lithium-responsive bipolar disorder? *Bipolar Disord*.; 15(8):824-31, 2013.

Parikh SV, Hawke LD, Zaretsky A, Beaulieu S, Patelis-Siotis I, Macqueen G, **Young LT**, Yatham L, Velyvis V, Bélanger C, Poirier N, Enright J, Cervantes P. Psychosocial interventions

for bipolar disorder and coping style modification: similar clinical outcomes, similar mechanisms? *Can J Psychiatry*.; 58(8):482-6, 2013.

Hajek T, Bauer M, Simhandl C, Rybakowski J, O'Donovan C, Pfennig A, König B, Suwalska A, Yucel K, Uher R, Young LT, MacQueen G, Alda M. Neuroprotective effect of lithium on hippocampal volumes in bipolar disorder independent of long-term treatment response. *Psychol Med*.; 44(3):507-17, 2013.

Andreatza AC, Wang JF, Salmasi F, Shao L, **Young LT**. Specific subcellular changes in oxidative stress in prefrontal cortex from patients with bipolar disorder. *J Neurochem*.; 127(4):552-61, 2013.

Schaffer A, Parikh SV, Kennedy SH, Milev R, Frey BN, Goldstein BI, Beaulieu S, Alda M, O'Donovan C, MacQueen G, McIntyre RS, Sharma V, Ravindran A, **Young LT**, Bond DJ, Lam RW, Yatham LN. Response to commentaries on the Canadian Network for Mood and Anxiety Treatments/International Society for Bipolar Disorders 2013 updated bipolar disorder guidelines. *Bipolar Disord.*; 15(3):338-9, 2013.

Andreazza AC, **Young LT**. The neurobiology of bipolar disorder: identifying targets for specific agents and synergies for combination treatment. *Int J Neuropsychopharmacol.* 2013 Mar 1:1-14. [Epub ahead of print

Soeiro-de-Souza MG, Andreazza AC, Carvalho AF, Machado-Vieira R, **Young LT**, Moreno RA. Number of manic episodes is associated with elevated DNA oxidation in bipolar I disorder. *Int J Neuropsychopharmacol.*; 16(7):1505-12, 2013.

Frey BN, Andreazza AC, Houenou J, Jamain S, Goldstein BI, Frye MA, Leboyer M, Berk M, Malhi GS, Lopez-Jaramillo C, Taylor VH, Dodd S, Frangou S, Hall GB, Fernandes BS, Kauer-Sant'Anna M, Yatham LN, Kapczinski F, **Young LT**. Biomarkers in bipolar disorder: a

positional paper from the International Society for Bipolar Disorders Biomarkers Task Force. *Aust N Z J Psychiatry.*; 47(4):321-32, 2013.

Che Y, Cui YH, Tan H, Andreazza AC, **Young LT**, Wang JF. Abstinence from repeated amphetamine treatment induces depressive-like behaviors and oxidative damage in rat brain. *Psychopharmacology (Berl.)*; 227(4):605-14, 2013.

Versace A, Andreazza AC, **Young LT**, Fournier JC, Almeida JR, Stiffler RS, Lockovich JC, Aslam HA, Pollock MH, Park H, Nimgaonkar VL, Kupfer DJ, Phillips ML. Elevated serum measures of lipid peroxidation and abnormal prefrontal white matter in euthymic bipolar adults: toward peripheral biomarkers of bipolar disorder. *Mol Psychiatry.* 2014 Feb;19(2):200-8. doi: 10.1038/mp.2012.188. Epub 2013 Jan 29. PubMed PMID: 23358158; PubMed Central PMCID: PMC3640681.

Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, O'Donovan C, MacQueen G, McIntyre RS, Sharma V, Ravindran A, **Young LT**, Milev R, Bond DJ, Frey BN, Goldstein BI. The evolution of CANMAT Bipolar Disorder Guidelines: past, present, and future. *Bipolar Disord.*; 15(1):58-60, 2013.

Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, O'Donovan C, MacQueen G, McIntyre RS, Sharma V, Ravindran A, **Young LT**, Milev R, Bond DJ, Frey BN, Goldstein BI, Lafer B, Birmaher B, Ha K, Nolen WA, Berk M. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. *Bipolar Disord.*; 15(1):1-44, 2013.

Scola G, Kim HK, **Young LT**, Andreazza AC. A fresh look at complex I in microarray data: clues to understanding disease-specific mitochondrial alterations in bipolar disorder. *Biol Psychiatry.*; 73(2):e4-5, 2013.

Hajek T, Cullis J, Novak T, Kopecek M, Blagdon R, Propper L, Stopkova P, Duffy A, Hoschl C, Uher R, Paus T, **Young LT**, Alda M. Brain structural signature of familial predisposition for bipolar disorder: replicable evidence for involvement of the right inferior frontal gyrus. *Biol Psychiatry.*; 73(2):144-52, 2013.

Zack M

Boileau I, Payer D, Chugani B, Lobo DS, Houle S, Wilson AA, Warsh J, Kish SJ, **Zack M**. In vivo evidence for greater amphetamine-induced dopamine release in pathological gambling: a positron emission tomography study with [(11)C]-(+)-PHNO. *Mol Psychiatry.* 2013 Dec 10. doi: 10.1038/mp.2013.163. [Epub ahead of print]

Zack M. Opioid and dopamine mediation of gambling responses in recreational gamblers. *Front Behav Neurosci.*; 7:147, 2013.

Selby P, Andriash K, Zawertailo L, Persad D, **Zack M**, Busto UE. Escalating doses of transdermal nicotine in heavy smokers: effects on smoking behavior and craving. *J Clin Psychopharmacol.*; 33(5):667-74, 2013.

Smart K, Desmond RC, Poulos CX, **Zack M**. Modafinil increases reward salience in a slot machine game in low and high impulsivity pathological gamblers. *Neuropharmacology.*; 73:66-74, 2013.

Boileau I, Payer D, Chugani B, Lobo D, Behzadi A, Rusjan PM, Houle S, Wilson AA, Warsh J, Kish SJ, **Zack M**. The D2/3 dopamine receptor in pathological gambling: a positron emission tomography study with [11C]-(+)-propyl-hexahydro-naphtho-oxazin and [11C]raclopride. *Addiction.*; 108(5):953-63, 2013.

Zawertailo L

Selby P, Andriash K, **Zawertailo L**, Persad D, Zack M, Busto UE. Escalating doses of transdermal nicotine in heavy smokers: effects on smoking behavior and craving. *J Clin Psychopharmacol.*; 33(5):667-74, 2013.

Le Foll B, Guranda M, Wilson AA, Houle S, Rusjan PM, Wing VC, **Zawertailo L**, Busto U, Selby P, Brody AL, George TP, Boileau I. Elevation of dopamine induced by cigarette smoking: novel insights from a [(11)C]-(+)-PHNO PET study in humans. *Neuropsychopharmacology.*; 39(2):415-24, 2013..

Chiuccariello L, Boileau I, Guranda M, Rusjan PM, Wilson AA, **Zawertailo L**, Houle S, Busto U, Le Foll B. Presentation of smoking-associated cues does not elicit dopamine release after one-hour smoking abstinence: A [11C]-(+)-PHNO PET study. *PLoS One.*; 8(3):e60382, 2013..

Zawertailo L, Dragonetti R, Bondy SJ, Victor JC, Selby P. Reach and effectiveness of mailed nicotine replacement therapy for smokers: 6-month outcomes in a naturalistic exploratory study. *Tob Control.*; 22(3):e4, 2013.

Kushnir V, Menon M, Balducci XL, Selby P, Busto U, **Zawertailo L**. Enhanced smoking cue salience associated with depression severity in nicotine-dependent individuals: a preliminary fMRI study. *Int J Neuropsychopharmacol.*; 16(5):997-1008, 2013.

Ph.D. Theses - Pharmacology Dept., University of Toronto (2013)

Bralha, Fernando (2013). The Role of Mitochondrial DNA Replication Fidelity in Toxicity Initiated by Drugs that Impair Mitochondrial Function. Supervisor(s): Rebecca Laposa & Dr. David Riddick.

Gamaledin, Islam (2013). Role of the Cannabinoid System in Modulating the Reinforcing and Relapse Related Properties of Nicotine in Rats. Supervisor: Dr. B. Le Foll.

Kabli, Noufissa (2013). Uncovering the Functional Implications of Mu- and Delta-Opioid Receptor Hetero-oligomerization. Supervisor(s): Dr. S.R. George & Dr. B.F. O'Dowd.

Lee, Frankie (2013). The Effect of Disc1 on Neurodevelopment in the Mouse. Supervisor: Dr. Albert Wong.

MacPherson, Laura (2013). 2,3,7,8-tetrachlorodibenzo-p-dioxin-inducible poly(ADP-ribose) polymerase is a mono-ADP-ribosyltransferase and a ligand-induced repressor of AHR transactivation. Supervisor(s): Dr Jason Matthews & Dr. Denis M. Grant.

Ptak, Carolyn (2013). Genetic-epigenetic Interactions: Sequence-Dependent and Independent DNA Methylation. Supervisor: Dr. A. Petronis.

Roedding, Angela (2013). Effects of Chronic Oxidative Stress on TRPM2 and TRPC3 Channels: Potential Implications for Bipolar Disorder. Supervisor: Dr. J.J. Warsh.

Zelner, Irene (2013). Screening for Prenatal Alcohol Exposure Using Meconium Fatty Acid Ethyl Esters as Biomarkers. Supervisor: Dr. Gideon Koren.

M.Sc. Theses - Pharmacology Dept., University of Toronto (2013)

Aleksandrova, Lily (2013) Pre-clinical Modelling of Treatment-Induced Impulsivity in Parkinson's Disease. Supervisors: Dr. J. Nobrega & Dr. D. Lobo

Baghai Wadji, Fariba (2013). Characterization of Abuse Properties of the Anesthetic 'Propofol' Using the Self-Administration Paradigm in Rats. Supervisor: Dr. Rachel F. Tyndale.

Bensimon, Kira (2013). The Inflammatory and Neuroanatomical Factors Involved in Post-Stroke Depression. Supervisor: Dr. Krista Lanctôt.

Bermejo, Kristel (2013). Measurement of Spine Density in Mouse Models of Hypodopaminergia. Supervisor(s) Dr. Ali Salahpour & Dr. Susan R. George.

Carnevale, Amanda (2013). Investigating the Use of Hair to Assess Polybrominated Diphenyl Ether (PBDE) Exposure Retrospectively, and in Male Infants with Genitourinary Tract Malformations. Supervisor: Dr. Gideon Koren.

Chang, Shunzhi (2013). Role of Extracellular-Signal Regulated Kinase (ERK) and cAMP Response Element Binding Protein (CREB) in the Incubation of Nicotine Craving. Supervisor: Dr. A.D. Le.

Chau, Sarah Thuy An (2012). Effect of Methylphenidate on Attention in Apathetic Alzheimer's Disease Patients and Association with Apathy Changes in a Randomized Placebo-controlled Trial. Supervisor: Dr. Krista Lanctôt.

Hanna, Daniel (2013). Sex and Strain Differences in Acute Hepatotoxic and Inflammatory Responses to Liver Procarcinogens in the Developing Mouse. Supervisor: Dr. Denis Grant.

Huzayyin, Aya (2013). Oxidative Stress and Global DNA Methylation in Patients with Bipolar Disorder and an Excellent Response to Lithium. Supervisor: Dr.L. Trevor Young.

Lam, Vincent (2013). Development and Validation of a Novel Quantitative Assay for Cell Surface Expression of GPCRs using a Receptor β -lactamase Fusion Protein and the Colourometric Substrate Nitorcefin. Supervisor: Dr. Ali Salahpour & Dr. Jane Mitchell.

Mazereeuw, Graham (2013). Platelet Activating Factors and Depressive Symptoms in Coronary Artery Disease Patients" Supervisor: Dr. Krista Lanctôt.

Miller, Rebecca (2013) The Expression and Regulation of CYP2D6 in a Monkey Model of

Mottaghi, Katayoun (2013). Structure-Based Development of Vitamin B5 Analogs and Evaluation of Their Antimicrobial Efficiency Against *S.Aureas* and *E. Coli*. Supervisors: Dr. H-W. Park & Dr. D.M. Grant.

Rajendra, Sharanya (2013). The Regulation of TiPARP by the Aryl Hydrocarbon Receptor, the Platelet-Derived Growth Factor Receptor, and the Estrogen Receptor Alpha. Supervisor: Dr. Jason Matthews.

Rovinski, Randal (2013). The Relationship Between Very Long Chain Plasma Ceramides and Anxiety in Coronary Artery Disease. Supervisor: Dr. Krista Lanctôt.

Ruddy, Rebecca (2013). Differential Effects of NMDA Receptor Antagonism on Spine Density. Supervisors: Dr. Amy Ramsey & Dr. Denis M. Grant.

Smart, Kelly (2013). Effects of Dopamine Antagonists on Gambling Reinforcement and the Impact of Prior Exposure in Pathological Gamblers and Controls. Supervisor: Dr. Martin Zack.